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Abstract (German) 
Die Herstellung von pharmazeutischen Wirkstoffen basiert zunehmend auf 
biotechnologischen Prozessen. Neben dem Zielmolekül treten dabei weitere Substanzen auf, 
welche entfernt werden müssen. In der Aufreinigung werden dafür oftmals mehrere 
Chromatographieschritte eingesetzt. Neben konventionellen Chromatographiegelen haben 
sich hier mittlerweile unterschiedliche membranbasierte Adsorber etabliert. Die 
Konzentration und Zusammensetzung von Kontaminanten als auch der Arbeitsbereich, wie 
pH-Werte und Leitfähigkeit, unterscheiden sich in Abhängigkeit des Expressionssystems, 
Reinigungsschemata und der chromatographischen Leistung. Membranadsorber, die eine 
hohe Verschmutzungsbeseitigung für eine breite Menge an Verunreinigungen in einem 
ausgedehnten Arbeitsfenster des pH-Werts und der Leitfähigkeit haben, sind daher von 
großem Interesse. Das Verständnis der Interaktion von Kontaminanten und Biomolekülen mit 
Membranadsorbern ist ein entscheidender Aspekt in der Entwicklung neuer Membranen 
sowie Reinigungsschritten in biopharmazeutischen Prozessen. Um besonders geeignete 
Liganden und Reinigungsbedingungen zu finden, sowie Prozesse besser zu verstehen, sind 
dabei jedoch oftmals umfangreiche experimentelle Untersuchungen notwendig. Um diesen 
Aufwand zu reduzieren, wurde daher in dieser Arbeit eine geeignete, applikationsorientierte 
Testmethode für die Untersuchung von Membranadsorbern im Kleinstmaßstab etabliert und 
bewertet. Diese ermöglicht eine parallele Charakterisierung von Eigenschaften des Adsorbers, 
um Zeit- und Materialaufwand in der Membran- sowie Prozessentwicklung zu reduzieren. 
Dazu wurden eine Vorrichtung zur Aufnahme des Membranmaterials und eine automatisierte 
Plattform entwickelt, mit welcher sich die chromatographischen Schritte abbilden lassen und 
die sowohl für analytische, als auch präparative Zwecke eingesetzt werden kann. Die 
Vorrichtung wurde bezüglich der Anwendungsmöglichkeiten und der chromatographischen 
Leistung im Vergleich zu größeren Einheiten bewertet. Anschließend wurden zwei 
Anionenaustauscher hinsichtlich ihrer Leistung zur Kontaminantenentfernung unter der 
Verwendung unterschiedlicher Modelllösungen charakterisiert. Ein Anionentauscher mit 
Ammoniumliganden wurde dabei mit einem salztoleranten Typen, basierend auf 
Polyallylamin, verglichen. Es wurden neue Ansätze untersucht, die eine Trennung von 
Zielmolekülen und Kontaminanten bei gleichgerichteter Nettoladung der Proteinoberfläche 
erlauben, z. B. durch die Zugabe geringer Mengen multivalenter Salze. 
Schlagwörter: Hochdurchsatzscreening, Kontaminantenentfernung, salztolerante 
Membranadsorber 
V 
Abstract (English) 
The production of active pharmaceutical ingredients is based increasingly upon 
biotechnological processes. Beside the target molecule there are a variety of undesirable 
substances that need to be removed. Often several chromatographic steps are used during 
purification. In addition to conventional chromatographic resins today different membrane-
based adsorbers have been established. The composition and concentration of contaminants, 
as well as the operating conditions like pH and conductivity values, vary depending on the 
biological expression system, purification scheme and the chromatographic performance. 
Membrane adsorbers with high contaminant-removal capabilities for a large variety of 
impurities in a wide operational window of pH and conductivity are of great interest in 
biopharmaceutical production. The understanding of the interaction of contaminants and 
biomolecules with membrane adsorbers is a crucial aspect in the development of new 
membranes and purification steps in downstreaming. In order to find the most effective 
ligands and purification conditions as well as the understanding of the process extensive 
experimental process development is necessary. 
To reduce the effort, an appropriate, application-oriented small-scale test method was 
established in this thesis and was evaluated for the investigation of membrane adsorbers. This 
enables the parallel characterization of properties of the adsorbent in order to reduce time and 
material consumption in membrane and process development. For this purpose a screening 
device for receiving the membrane material and an automated platform were developed, 
which can be used to represent typical chromatographic steps as well as for analytical and 
preparative purposes. This membrane adsorber screening platform was estimated regarding 
possible applications and the chromatographic performance was compared to larger devices. 
Following different anion exchangers were characterized in terms of performance for 
contaminant binding in a wide range of pH and conductivity. An anion exchanger with 
ammonium ligands was compared with a salt-tolerant type based on polyallylamine ligands 
using different models. New approaches were investigated which allow a separation of target 
molecules and contaminants at similar net charge of the protein surface, e.g. by the addition of 
small amounts of multivalent salts. 
Keywords: high-throughput screening, contaminant removal, salt-tolerant membrane adsorber 
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1 Introduction 
The demand for biopharmaceuticals is steadily growing [1-3]. The main reasons are the 
ongoing demand and development of new therapeutic approaches and diagnostics using 
recombinant proteins like hormones, clotting factors, antibodies, growth factors or vaccines. 
For example, monoclonal antibodies are used for therapy of cancers, autoimmune diseases or 
diagnostics. Even in 2006 the number of approved antibodies was over 20 and more than 160 
had been examined for launch [4]. The sales of monoclonal antibodies reached 30 billion US 
dollars in 2008 [5]. Furthermore, a high potential is attributed to recombinant viral vaccines 
for gene therapy or vaccination. For those applications probably a large amount of virus 
particles is required [6].  
Despite of the trend of growing diversity and sales, the development of economic 
bioprocesses under shorter timelines is required [7, 8], because e.g. more stringent safety 
regulations increase the costs of clinical trials [1, 9]. Furthermore, a cost reduction could 
improve the access to emerging markets and drives the production of biopharmaceuticals for 
rare diseases. 
For the production recombinant eukaryotic and prokaryotic expression systems are used. 
During the cultivation, including the growth of cells and product formation, additionally to the 
target molecule a multiplicity of contaminants occur. Host cell proteins, viruses, adventitious 
protein aggregates, endotoxins or nucleic acids could lead to undesired effects for the product 
itself or the patient. The nature, composition and quantity of components to be removed 
during downstream processing vary depending on the expression system, nutrient solution and 
process conditions used for cultivation. The therapeutic effectiveness or stability can 
decrease [10]. Furthermore, contaminants are responsible for adverse health effects after 
administration. This is caused by the contaminant itself or changed active agents. The immune 
reaction caused by the contaminating substances can lead to complications during the 
therapy [11, 12]. Thus, for the approval of biopharmaceuticals, e.g., by the Food and Drug 
Administration or the European Agency for the Evaluation of Medicinal Products, all 
interfering impurities have to be reduced down to an acceptable level. Depending on the 
amount of dose, guidance values for the permitted amount of impurities per dose exist. 
Following the cultivation and the cell harvest, downstream processing includes several steps 
to purify and concentrate the target molecule. Here chromatographic processes based on size, 
ionic exchange, affinity or hydrophobic interactions are essential procedures. The 
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2 
performance of these steps depends on the composition of contaminants as well as the 
window of process conditions like pH, conductivity or buffer composition. In addition to 
traditional chromatographic resins, in recent years further technologies using adsorptive 
materials were implemented in downstream processing. Membrane adsorbers distinguish 
themselves especially due to the high-throughput, the effective utilization of the binding 
capacities and performance in the binding of larger molecules compared to chromatographic 
resins [13-17].  
Based on the aforementioned facts the present work focuses on the development and 
evaluation of fast test procedures to characterise membrane adsorbers for contaminant 
removal using small-scale approaches. This is the fundament for the improvement of 
knowledge in contaminant removal with membrane adsorbers, the development of new 
applications and process optimisation. The focus is on the investigation of anion exchangers 
for applications in downstream processing. The properties of a standard and new salt-tolerant 
membrane adsorber are compared. 
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2 Objectives 
The improvement of the use of membrane adsorbers in pharmaceutical bioprocesses can be 
divided into two areas: the development of membranes and the improvement of process 
understanding including the knowledge about interaction between target molecule, 
contaminants and membrane adsorber. For the implementation and characterization of 
membranes the three major objects are of interest: 
 1)  A suitable device was necessary to generate a better understanding of the performance 
of membranes. The primary requirements were adapted to the use in the early stage of 
membrane and process development. Typically only small amounts of new modified 
membrane material or process solutions containing the molecule of interest are 
available. To accelerate development a quick installation and a simultaneous 
measurement of several process conditions or composition of target molecules and 
contaminants should be possible. The amount of materials for the tests has to be as 
small as possible. 
 2)  For the measurement of a broad operational window of conditions the complexity in 
providing appropriate process solutions is a drawback. Furthermore, the amount of 
work for sample analysis increases. Therefore, an automated platform was established 
to characterise membrane adsorbers. It enables the flexible preparation of typical 
process buffers and protein solutions. The platform carries out all the pipetting steps in 
order to mimic a real chromatographic process sequence. A 96-well plate reader for 
the analytics is directly adapted to the automated platform.  
 3) The screening system was used to define process conditions and membrane properties 
  which are crucial for contaminant removal. The focus was on the comparison of a 
  well-established and a new salt-tolerant anion exchange membrane adsorber. The 
  knowledge should improve the understanding of a useful operational window during a 
  purification step identifying critical parameters and evaluate new polishing strategies 
  to separate contaminants and target molecules. 
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3 Theoretical backgrounds 
3.1 Design of biopharmaceutical downstream processes 
In principle there is no general approach for a successful production process. Instead, several 
process steps have to be implemented due to the expression system used and necessary safety 
requirements. For the release and marketing of a given biopharmaceutical, regulatory 
authorities request the use of different technologies during downstream processing to ensure 
the reduction of critical impurities like viruses. The target molecule can be produced using 
different cell lines like bacteria, mammalian or insect cells [18, 19]. Furthermore, yeast or 
plant cells are used [20]. After cultivation cell harvest initiates the transition of the target 
molecule to downstream processing. The necessary steps needed for the cell harvest basically 
depends on the cellular location of the target. If the product is not secreted into the media by 
the cell or microorganism, a cell disruption prior the separation of cell and target is necessary. 
For the release of target molecule physical (grinding, decompression, freezing and thawing, 
ultrasound), chemical (treatment with acid or extraction with acetone) or biological methods 
(enzymes, phages) can be used [21]. To remove unwanted, preferably insoluble components 
centrifugation, flotation or microfiltration is applied. Also during cell harvest it is preferable 
to remove contaminants like HCP, endotoxins or DNA. Examples are the reduction by depth 
filter materials [22] or precipitation [23]. Therefore, such process steps get a smoother 
processing from cultivation to final downstream processing.  
General aims of downstream processing are the separation of the target molecule (product) 
from contaminants, adjusting the required concentration and stabilisation of the drug 
substance and using a storage medium for final filling. It should be of the highest purity and 
recovery possible. For concentration and purification several steps are used which can have an 
impact on all aforementioned aims. In the following the most common techniques are 
described and evaluated in terms of operational performance. The assessment refers primarily 
to the use in a process scale.  
(Ultra-) Centrifugation uses centrifugal forces to separate components by density [24]. This 
technique is rather expensive. Because of the limitations regarding scalability, large-scale 
production and continuous processing, process developers try to avoid this technology [25]. 
Like with precipitation, extraction or crystallisation, centrifugation requires a further step to 
separate the resulting phases. The pellet can be dissolved in a different buffer, which is 
required for further purification steps or stabilisation of the product. 
Theoretical backgrounds 
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Filtration is a major part of downstream processing. As a function of pore size microfiltration 
(> 0.1 µm) and ultrafiltration (0.01 – 0.1 µm) are common used techniques. Sterile filtration 
removes microorganisms while the product passes the filtration unit [26]. Cross-flow filtration 
separates dissolved components in a solution using membranes with a defined molecular cut-
off. Depending on the size the target molecule is retained or passes the membrane. While 
during dead-end filtration a growing filter cake reduces flux, cross-flow filtration has the 
advantage that the filter cake is washed away by tangential flow over the filter area. In the 
case that the target molecule is retained, it is furthermore possible to increase its concentration 
in the retentate. A special embodiment of cross-flow filtration is diafiltration. The target 
molecule will be retained by the membrane while small molecules like contaminants, water 
and medium ingredients pass through the membrane. By adding new buffer to the circulating 
retentate it is possible to change the buffer [27]. To assure virus clearance, beside virus 
inactivation by ultraviolet radiation, antiviral agents or low pH, size exclusion based virus 
filtration can be used [28, 29]. 
Chromatography is a well-established step in the reduction of contaminants and/or the 
concentration of the product. In biopharmaceutical processes ion exchange, hydrophobic 
interaction and affinity are the most common separation mechanisms of chromatography. 
Here, two modes of operation are practical. In flow-through mode the target molecule passes 
through the chromatographic media (stationary phase) ideally without an interaction 
(binding). Whereas, contaminants interact (bind) to the chromatographic media and are 
retained. This mode of operation is often located near to the end of a downstream process. 
The second mode is bind and elute. The target molecule binds preferably to the stationary 
phase whereas most of the contaminants pass through. Non-bound components are removed 
with a washing step. Furthermore, bind and elute enables the removal of contaminants using 
specific washing steps or elution profiles. Finally, the use of a different buffer initiates the 
release of the bound target molecule by quenching or weakening binding forces. In contrast to 
flow-through mode, bind and elute additionally increases the product concentration by using a 
smaller amount of elution buffer compared to the volume of the applied solution of the target. 
While the reduction of contaminants, often also called purification or polishing step, can be 
done in flow-through or bind and elute mode, capture chromatography or capturing describes 
the binding of the target molecule to an adsorbent [13, 30, 31]. 
Theoretical backgrounds 
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Figure 1: Mode of operation in chromatography for contaminant removal. In flow-through (A) the filtrate 
ideally contains only the target molecule, while contaminants of the feedstream bind to the adsorbent. Bind and 
elute takes place in at least two steps: During loading (B1) the target molecule binds to the adsorbent, whereas 
the contaminants preferably pass through. In a second step (B2) the target molecule is removed by the 
displacement or weakening of the interaction. 
After purification and concentration, formulation by drying, crystallisation or final filling is 
used for preservation of the active drug substance [32]. 
The following flow charts illustrate two potential processes for the production of monoclonal 
antibodies (mAb) [17, 33-35] and viral vaccines [36]. Widespread mAbs are used in 
diagnostics and for therapeutic treatment [37], viral vaccines for immunization. Special forms 
of viral vaccines are virus-like particles which do not contain genetic material [38].  
 
Figure 2: Typical downstream process schemes. Cultivation and cell removal is followed by downstream 
processing. Several chromatographic steps generate a product of high purity. Between the above steps, further 
procedures of concentration and buffer change are optional possible.  
Due to the costs of the downstream processing related to the overall production process costs 
[1, 16, 33, 39-41] industry continues to search for approaches to skip process steps or using 
alternative technologies like ultracentrifugation. To reduce the development timelines and 
costs of production, manufacturers try to implement basic process platforms, for example, the 
use of a certain cell line with the same process steps for the production of different 
biopharmaceuticals [42-44]. The switch to disposable systems is currently a trend in the 
 A B1 B2
Matrix with 
Adsorbent
Target molecule
Contaminant
Flow direction
Affinity
Virus 
clearance
Ion exchange Ion exchange
Virus 
clearance
Ultrafitration 
Diafiltration
Bind and elute Bind and elute Flow-through
Monoclonal antibody
Ion Exchange
Hydrophobic 
interaction
Ion Exchange
Ultrafitration 
Diafiltration
Bind and elute Flow-through
Viral vaccine
Bind and elute
Form and 
Filling
Form and 
Filling
Theoretical backgrounds 
7 
market place that aims to simplify process preparations and avoid expensive validation of 
equipment-cleaning procedures. Other possibilities are to improve the already well-known 
purification steps. General continuous downstream process steps are an improvement. For 
example, the simulated moving bed for chromatography has long been cited as being able to 
overcome limitations on the size of chromatography devices and the associated non-
continuous processing of larger volumes [29, 45, 46]. 
 
3.2 Contaminants in downstream processing 
Contaminants or impurities are unwanted substances derived from either the environment or 
the production process. In general, they are classified process- or product-related impurities. 
Product-related impurities are undesired variants of a product such as protein aggregates, 
aberrant glycoforms or oxidized forms [42, 47]. In contrast, process-related impurities mainly 
caused by the host cell organism, extractables of materials which come into contact with 
process media or components of the fermentation media. Added anti-foam agents or 
antibiotics will also need to be removed before final filling of the product.  
The administration of contaminants, for example, subcutaneous or intravenous, can trigger the 
immune response of an organism. Further, it can act as a poison or reinforce the effects of a 
drug (adjuvant). The effect is short-term illnesses, but can also lead to chronic disease or 
death [35, 47, 48]. For this reason, biopharmaceutical manufacturers must ensure that their 
products are free of impurities. Limits were defined based on studies of the effect of various 
substances. Some substances will be removed below the detection limit, but generally 
accepted values are rarely found because this depends on the maximum administration of a 
certain drug to the patient. However, there are some suggested guidelines. The manufacturer 
has to demonstrate to the authorities that the impurities in question are within the suggested 
limits. 
A large amount of impurities or contaminants are produced by the host cells itself. Cells 
contain e.g. components like proteins and lipids to enable cell functions and stabilize the cell 
structure. Some constituents, cytotoxins or degradation products are released already during 
the lifecycle, while others will be set free as a consequence of cell lysis. The major 
contaminant groups are the following: 
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Host cell proteins (HCP) are defined as proteinaceous cell constituents different from the 
target recombinant product [12, 49, 50]. Their various functions they are indispensable for the 
normal cell functions like e.g. growth and multiplication. Differences are in size, shape, 
physical and chemical properties such as the isoelectric point. This diversity often makes it 
necessary to use several purification mechanisms to achieve a sufficient clearance from the 
target molecule. The initial content of HCP can be up to several grams per litre. After a first 
affinity chromatographic step in the mAb processes, the concentrations were up to 
10000 ppm [3]. 
Nucleic acids (Desoxyribonucleic and Ribonucleic acid) are essential molecules containing 
genetic information and are necessary for the synthesis of proteins. As a rule of thumb the 
amount should be 10 to 100 pg per dose for a given biopharmaceutical [51, 52]. In organisms 
DNA is present in the form of a double helix structure. Theses nucleic acids (NA) may appear 
either in small circular molecules or in chromosomes with lengths up to several millimetres. 
NAs are highly negatively charged because of the phosphate groups in the backbone of the 
molecule. Therefore, the method of choice is the removal with anion exchangers in the form 
of resins or membranes. 
Viruses are infectious parasitic particles. The main components are viral DNA or RNA for 
replication together with structural proteins for e.g. the capsid. They are only able to 
reproduce with the aid of the metabolism of the infected cell. The risk of the presence of virus 
depends for some instance on the used cell line too. Particular features of viruses are the size 
of 5 to > 100 nm [53] that means tiny in comparison to other cell constituents but large to the 
soluble proteins like mAb. Furthermore, some viruses have an additional envelope outside to 
the capsid structure, a lipid bilayer with integrated proteins necessary for docking to and 
penetrating the cell surface [30, 36, 54, 55]. Different sources can be distinguished for viral 
contamination. Adventitious viruses are accidently introduced during the handling in process, 
e.g. by contaminated cell culture media, equipment and reagents, the operator or the latent 
infection of a cell line. Endogenous viruses originate from the host cell itself and are inherited 
as part of the genome [56]. 
Other contaminants, which can cause severe problems in humans like fever or anaphylactic 
shock syndrome, are endotoxins. They are lipopolysaccharides and can be released from the 
outer membrane of gram-negative bacteria [57, 58]. The effects are fever and inflammation. 
In severe cases, it can lead even to death by septic shock [59]. In general, endotoxins are 
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omnipresent. For example, the concentration of endotoxins in drinking water is between 1 and 
20 endotoxin units (EU) per millilitre. In gram negative bacteria cultivation e.g. Escherichia 
coli the endotoxin level can be high as 1.000.000 EU/ml. In animal cell cultures it is often less 
than 100 EU/ml [60, 61]. EU is the unit for the endotoxins which based on its biological 
activity. Thus, it can be vary between different sources. The FDA released a reference 
standard of endotoxins, which is currently determined with 10 EU per ng endotoxin [62]. Due 
to their negative effects, endotoxins must be removed to < 0.25 EU/ml for sterile water for 
injection [63].  
Aggregates are incorrectly folded and/or associates of proteins and have to be removed from 
the correctly folded native proteins. Non correct folding of the protein structure can lead to 
hydrophobic amino acid residues being exposed to the surface of the protein. Upon that 
change in the conformation, interactions with other proteins can lead to aggregation to larger 
complexes. Strong aggregation of some proteins can cause protein precipitation, while others 
retain their solubility [9, 48]. Aggregates can be formed by chemical, thermal or other 
physical effects. Mechanical shear can destroy the structure of proteins [64-68]. An example 
is the bursting of bubbles in the fermentation reactor, leading to damaged proteins appearing 
in the foam [69, 70]. In certain buffers or at low pH, proteins are less stable and tend towards 
aggregation [71]. The amount of aggregates to be removed varies at different processes: in a 
mAb process it can be between 1 and 20 % of the target protein [3]. The proportion of e.g. 
mAb aggregates often increases with increasing amount of protein present [71, 72]. 
Furthermore, the process may be reversible. A change in buffer conditions helps to dissociate 
the aggregate complex into the monomer units [73].  
Furthermore, during the downstream process different contaminating substances, called 
leachables, can be released from the equipment used. For example, fragments of the ligands of 
chromatographic resins are released in an affinity chromatographic step from a Protein A 
resin [28]. Leachables are suspected to promote the formation of aggregates [74]. Compared 
to other contaminants the levels are rather low [3]. But Protein A is a certain concern because 
of the multiple effects of that molecule to the human organism [75]. 
The evaluation of the effect on product purity and thus adverse reaction by different 
contaminants is complex. Process impurities often cause product-related ones by e.g. 
increasing the formation of product aggregates [22]. Proteases can degrade the target 
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proteins [11]; contaminants often affect each other thus abolishing the predictability and 
prevent a generalization of the contaminant composition.  
In addition to the removal of contaminants during downstream processing, a general goal is 
the prevention of their formation. A proper selection and correct operation of expression 
system or adding the amino acid arginine into the Protein A affinity chromatography step to 
reduce protein aggregation are only two examples described [50, 76]. 
Much attention during the purification of pharmaceutical products like mAb is thus paid to the 
detection of possible contaminants. Table 1 lists relevant analysis methods for the most 
important substance classes. The respective assays used in this thesis are described in the 
Appendix. 
Table 1: Generic methods for contaminant detection and quantification. 
Substance Assay Remarks 
DNA PicoGreen, PCR
1
 Real-time PCR
1
  
Host Cell Proteins ELISA
2
  
Leached Protein A ELISA
2
  
Aggregates SEC
3
 Detection at 280 nm 
Viruses PCR
1
, plaque assay Model Virus ΦX174  
Endotoxin LAL
4
 Gel clot / chromogenic 
1
 Polymerase chain reaction 
2
 Enzyme linked Immunosorbent 
3
 Size exclusion chromatography 
4
 Limulus Amebocyte Lysate 
 
3.3 Membrane adsorbers 
In general membranes used in downstream process applications are a separating layer 
exhibiting sieving effects like e.g. virus or sterile filters. Microfiltration is defined at pore 
sizes rating from 0.1 – 15 µm, ultrafiltration with nominal molecular cut off values ranging 
from 2 – 1 Mio Dalton. This classification is somewhat arbitrary. The performance of 
membrane adsorbers is based on the same mechanisms exploited in liquid chromatography 
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with resins. A mixture of substances is separated by different distribution between the solid 
stationary phase (here: membrane) and a mobile liquid phase. For membrane adsorbers, also 
known as membrane chromatography, ligands are attached to the large inner surface of a 
membrane matrix by e.g. grafting or coating processes [77, 78].  
The membrane adsorbers, which were used in this thesis, are based on reinforced regenerated 
cellulose with a nominal pore size of 3 – 5 µm [79, 80]. An advantage of this membrane 
material is the low nonspecific binding for various biomolecules. This eliminates unwanted 
and difficult-to-control adsorptive mechanisms. During manufacturing a polymer chain 
structure is applied (grafting) to the entire inner pore surface or to partial regions of the basic 
membrane respective, e.g. polyacrylates with epoxy groups. These chains are forming the 
reactive layer for the attachment of various ligands. The chromatographic active layer in the 
pores typically has a thickness of less than 1 µm leading to a negligible diffusion limitation of 
mass transfer which is the most important feature of membrane adsorbers compared to 
commercially available resins on the basis of agarose e.g. Sepharose™ or other beaded 
polymers [17, 80-84]. An additional feature is ready-to-use i.e. out of the box, simple 
handling and operation and single use application. A feature of interest of adsorptive media is 
the binding capacity for the target. Although membrane adsorbers are planar structures, for a 
comparison the capacity is given not only as weight per membrane area but also in weight per 
volume. This originated from a historical perspective, since the amount of resins is given as a 
volume. Some ligands and the separation mechanism used for membrane adsorbers and resins 
are listed in Table 2. 
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Table 2: Chromatographic ligands of membrane adsorbers and interactions. In contrast to weak, strong ion 
exchanger binding properties are less sensitive to the pH. The ligands are present in dissociated form in broad pH 
range. 
Ligand / functional group Interaction 
Sulphonic acid Strong cation exchanger 
Quaternary ammonium Strong anion exchanger 
Primary amine Weak anion exchanger 
Protein A Affinity 
Phenyl Hydrophobic 
Iminodiacetic acid Metal chelate 
 
In commercially available devices often a stack of several layers of flat-sheet or wound 
membranes are used to increase the built-in membrane volume [27, 81]. Applications are 
described where the process fluid is passed tangentially over both sides of the adsorbing 
membrane thus allowing the processing of particle-containing solutions [85]. 
In contrast to the open-porous structure of membrane adsorbers, column chromatography 
resins consist of a packed bed of porous chromatographically active beads. Thus, resins have 
a higher specific inner particle surface which leads to a higher binding capacity compared to 
the macroporous membrane-based adsorbers. Due to the high packing density and dead-end 
pores of the beads a disadvantage of resins is the molecular diffusion into and out of the pores 
of the beads. Here driving forces for the mass transfer are Brownian motion and a 
concentration gradient [86, 87]. Therefore, the time required for the molecules to reach a 
potential ligand is much higher than for membrane adsorbers where the mass transfer occurs 
mainly by convention rather than diffusion [77]. Thus, the binding kinetic of molecules is 
independent in a broad range from the residence time for membrane adsorbers, but not for 
resins. Furthermore, the packing density of a packed bed is high and causes a high flow 
resistance and hence a high pressure drop. From a certain bed height usually 10 – 15 cm the 
scale up is only possible by the enlargement of the column cross-section. Although the 
binding capacity of resins for small molecules is higher than for membrane adsorbers, larger 
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molecules are less or unable to diffuse into the pores. Larger target molecules which bind to 
the outer region of the beads blocked the pores and prevented the entrance of other molecules 
into the interior of the bead [16, 41, 78, 80, 88]. This effect additionally is an advantage of 
membrane adsorbers for the adsorption of larger target molecules. A higher binding capacity 
for viruses is described [43]. 
Further alternatives to conventional chromatography in downstream processing are 
chemically modified hollow-fiber modules [89] or monoliths [90, 91]. These systems also 
have the goal to reduce the flow restrictions and limitations in capacity of resins. Moreover, 
like membrane adsorbers they improve the handling since no packing of a gel bed is 
necessary.  
One of the most generic steps in contaminant removal is ion exchange chromatography. The 
separation step is based on the charge of molecules at different pH values. Depending on the 
pH, the ionized amino acid side chains of proteins influence the net charge [92, 93]. For 
example, the negatively charged groups predominate, thus the protein binds to a positively 
charged ion exchanger. The isoelectric point (pI) describes the pH where the net charge of the 
protein is zero. If the pH is below the pI, a protein is positively charged. A high pI of a 
monoclonal antibody favors the use of an anion exchanger in the neutral pH range because 
most contaminants have a negative charge (Figure 3). 
 
Figure 3: Charge of contaminants and antibodies. At a pH around 7 a polishing step using an anion exchanger 
is preferred in flow-through mode due to the negative charge of most contaminants and a positive charge of the 
target molecule (mAb). The distribution of contaminants reflects an ideal situation. Measurement of the 
isoelectric points of viruses revealed that a binding at neutral pH is also possible [93]. 
The strength of binding a protein to the ligand depends on the amount of charged chains and 
their accessibility. However, proteins and equally charged ions compete for the adsorption 
sites. The affinity of salt ions is generally higher than of proteins. This can be used to elute 
bound protein molecules from the ion exchanger. Furthermore, proteins with different electric 
charges can be separated by adjusting the ionic strength e.g. continuously by applying a salt 
gradient. Since salt ions present in process solutions can prevent the binding of target 
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components need for dilution which leads to higher process volumes and requires high 
volume vessels on diafiltration to remove salt, the aim is to develop ion exchangers which 
also bind e.g. proteins at higher ion concentrations in the solution. These are referred as  
salt-tolerant ion exchangers [94, 95].  
 
3.4 Bottlenecks in process development 
Previous chapters provide an overview and illustrate the complexity of biopharmaceutical 
production. Nowadays there are expression systems with a challenging array of biological 
impurities and different chemical properties of the cell culture media. This is accompanied by 
a limited knowledge of contaminant composition and their mutual interactions or influences 
on the different process steps. Nevertheless, it is desirable to design the downstream process 
at an early stage. A robust process with an effective purification train accelerates the entry 
into the time-consuming clinical trials where effects and adverse reactions of the 
biopharmaceutical are investigated. Furthermore, regulatory requirements increase the 
demand on understanding the process steps thus developing drugs and processes which 
promote lowest health risks for the patient during administering the drug [96-98]. 
The development of a biopharmaceutical production always starts at small scales. After 
selecting a suitable modified microorganisms or cell line, the cultivation and the production of 
the target molecule are optimized. This is performed in the so-called upstream process. 
Furthermore, only small amounts of fermentation broth or cell culture medium is available for 
simultaneously establishing the purification strategy (downstream). Later in the development 
of the purification train it is often difficult or even impossible to change a purification step, 
because if a procedure is changed or replaced at a larger scale, it can have an impact on the 
product quality. This would unnecessarily boost costs and slow down progress due to 
additional regulatory effort and trials in clinical phases. Therefore, effective methods and 
small-scale devices are required. So it is obvious that new technologies are difficult to 
establish, because small-scale approaches are not available or insufficiently scalable. 
There may be similar problems with development of purification technologies. For instance in 
chromatography more suitable ligands or matrices would be valuable and necessary. 
Performance influencing variables which can be manipulated are e.g. the pore size or ligand 
density of an ion exchanger membrane. To characterize the performance of new adsorptive 
media model proteins like bovine serum albumin are used [41, 95, 99]. However, model 
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systems do not represent a real application [100]. The binding behaviour of target molecules 
from complex media is often completely different and interactions are sometimes 
unpredictable. A structural change of a membrane not only may have an impact on its binding 
capacity, but also on the selectivity [54]. Even more difficult to predict are chromatographic 
approaches with mixed mode adsorbents. Such media combine different adsorption 
mechanisms like ionic exchange and hydrophobic interaction [31, 101, 102]. 
The limited availability of real process media and a high number of influencing parameters 
accelerates the development of new small-scale purification screening approaches. To get rid 
of these development bottlenecks several techniques have been established. As a “toolbox” 
high-throughput screening (HTS) techniques are well known in the pharmaceutical and 
chemical industry, especially in the drug discovery [103]. In general high-throughput 
describes the parallelization of simultaneous running operations. It enables a systematic 
examination of a multiplicity of parameters or combinations, for example, the investigation of 
several additives on cell growth during fermentation. This includes a high statistical reliability 
and less consumption of raw materials. Important topics of HTS are experimental design, 
automation and data analysis.  
In the last decade high-throughput downstream screening approaches have emerged. The field 
of application mainly addresses chromatographic steps in the downstream development with 
resins. In 2005 one of the first resin-based 96-well product was described [104]. It consisted 
of a combination of several small-scale columns and was designed for a parallel column 
chromatography with a liquid-handling robotic workstation operated similar to large-scale 
columns, wherein the mobile phase flows through the packed bed continuously [100]. A 
second approach emerged with resin filled 96-well plates for screening. In 2010 the screening 
of process conditions for a Protein A affinity chromatography capturing step was described. 
The study showed the approach for the optimization of buffers for protein binding, washing 
and elution regarding contaminant removal and product recovery. In contrast to small resin 
columns the use of 96-well plates is a batch adsorption process [106]. The small cavities with 
a few µl of resin are filled successively with the solutions used in a chromatographic 
operation (Figure 4).  
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Figure 4: Chromatography resin screening. 96-well plate for resin small-scale screening approach. Small 
cavities are prefilled with 2-50 µl resin. After filling with liquid the plates will be shaken. A centrifuge or 
pressure gradient is used to remove the liquid. Resin beads are retained by the supporting material at the bottom 
of each well. 
To mimic the flow in the column the liquids are shaken until equilibrium. The resin is placed 
on a supporting material and after the incubation the supernatant liquids are after centrifuged 
and aspirated for analysis [107, 108]. The batch experiments enable the mimicking of a whole 
chromatographic process (Figure 5). As mentioned, residence time is fundamentally important 
parameter for the operation of resins. Its determination is a basic application when screening 
chromatographic resins. Results show a shifting of the separation optimum by changing the 
residence time.  
 
Figure 5: Chromatographic steps. Depending on the mode of operation only the necessary chromatographic 
steps are performed. Conditioning and equilibration prepare the adsorbent. Manufacturing-related impurities are 
removed and the equilibrium condition between the solid and mobile phase are reached. The load is the 
application of the solution containing target substances and contaminants to the column. In bind and elute mode 
additional wash steps shall remove contaminants. Regeneration is added if the adsorber material is to be used 
again. 
High-throughput applications need technologies for a sufficient sensitive analysis of samples. 
Due to the standardized formats (96-well) and automation there are only limited restrictions. 
The investigation of HCP or antibody purification with Protein A resins using high-
throughput approaches are described [109]. Furthermore, a platform technology including the 
automation of chromatographic steps and analysis of samples for the screening of 
chromatographic resins is demonstrated in downstream processes [106].  
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In terms of membrane chromatography a simple calculation illustrates the demand on material 
required for the investigation of a polishing step. For contaminant removal at the end of a 
process chain only a small amount of impurities in relation to the target molecule are 
remaining. Thus, only a small amount of adsorptive media is required. Because of high 
possible flow rates membrane adsorbers are ideally suited and an oversizing is not necessary 
like with resins. But scale down of these processes conditions cause a problem. Due to the 
high binding capacity for the residual low concentrated contaminants the total load of the 
target protein per adsorber volume is high. Studies showed that up to 15 kg per litre of 
membrane can be processed [110, 111]. For small scales this means even for a membrane 
volume of 1 ml up to 15 g mAb is necessary to reflect a process condition. This highlights the 
need for small-scale approaches in membrane chromatography. Figure 6 summarizes the use 
of high-throughput screening. It contains the application and membrane adsorber 
development. In addition to the optimization of the parameters for applications, screening is a 
tool to investigate process strategies and robustness. In membrane modification and 
manufacturing, the use of different model contaminants or proteins offers a rapid evaluation 
of the parameters influencing the manufacturing process.  
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Figure 6: Use of screening in membrane chromatography. The chart presents an overview of potential use in 
the application- and membrane adsorber development. Strategies: the selection of chemistry and step position in 
the purification process. Optimization: Investigation of the influence of buffer composition and type of proteins. 
Robustness: Exploration of the design space to assess the effect of process variations on the chromatographic 
step and its robustness. Modification: The use of model systems triggers the evaluation of new ligands and 
applications. Manufacturing: Effects of changes in process parameters like temperature or chemicals on the 
stability of the membrane surface (homogeneity). 
Several small-scale approaches for high-throughput screening using membrane adsorbers 
were published. In Table 3 96-well high-throughput applications for resins and membrane 
adsorbers are summarized. Furthermore, HTS applications applied in bioprocess development 
are reviewed in [108]. 
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Table 3: High-throughput applications in resins and membrane based chromatography.  
Published Screening media/device Application 
2005 [112] Resin 100 µl/well, 96 well plate Purification of recombinant proteins 
2006 [113] Membrane adsorber 1.6 cm²/well (44 µl), 
8-strip 96 well plate 
Isolation of model proteins and polyhistidine-
tagged proteins 
2007 [109] Resin 200 µl/well, 96 well mini columns Removal of HCP from mAb 
2008 [105] Resin 50-100 µl/well, 96 well plate Removal of high molecular weight product-related 
impurities from mAb  
2008 [115] Resin 100 µl/well, 96 well plate Removal of aggregates from mAb 
2008 [116] Resin 50 µl/well, 96 well plate Removal of HCP from mAb 
2008 [117] Resin 2 µl/well, 96 well plate Binding of polyclonal human immunoglobulin and 
amyloglucosidase 
2010 [118] Resin 25 µl/well, 96 well plate Removal of HCP and aggregates for a polishing 
step in mAb production 
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4 Implementation of a 96-well HTPD platform for the 
characterization of membrane adsorbers 
4.1 Device and screening platform 
The first chapter of the practical part of this thesis deals with the development of a suitable 
screening approach for membrane adsorbers. This includes the construction of a device which 
enables the operation with flat-sheet membrane layers. The properties of the device are 
tailored to work with contaminants as mentioned in Chapter 3.2 and fulfil the screening 
format requirements. To accelerate the screening process the device is adapted to an 
automated liquid handling platform. Regarding the chromatography steps the main 
performance characteristics are explained and examined. 
 
4.1.1 Development of a reusable 96-well device 
Essential features for the device are dictated by the limited availability of raw material and 
sample size. In small-scale fermentation only small amounts of process media are available, 
also in membrane development processes chemical-modified samples are available only in 
small quantities. Therefore, to obtain as much of information about a specific modification of 
a membrane as possible a simple approach is required. Furthermore, a miniaturization should 
enable a parallelization to reduce the required time for generating characteristic data in 
membrane chromatography. The small-scale approaches for membranes described or 
commercially available are based on multi-well devices with separate membrane material i.e. 
the incorporation of discrete membrane pieces into each single well of the plate which causes 
problems with sealing and increases complexity of assembly like used in [113, 114]. The use 
of well plates with consist of chromatographic resins is time-consuming because of required 
residence time to achieve equilibrium [117]. To circumvent these obstacles a holder was 
developed which enables the use of single continuous flat-sheet membrane adsorber layers, 
which forms discrete wells. A sealing prevent a cross-talk caused by lateral diffusion between 
individual wells.  
Figure 7 and 8 show the holder construction whose dimension are adapted to the standard 
format of consumables like 96-well plates [119] or UV-transparent plates suitable for 
analysis. The holder is compatible with standardized robotic liquid-handling systems. 
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Figure 7: Homemade 96-well membrane holder construction. A: Exploited view of the device with 
membrane adsorber sheet; B: cross-section of the device; (1) top part, (2) bottom part, (3) stack or single sheet of 
membrane, (4) membrane stack receiving surface, (5) cavity for applying samples, (6) permeate outlet funnel, 
(7a) sealing surface bottom part, (7b) sealing surface top part, (8) threaded bore, (9) bore for screwing bolt, (10) 
capillary, (11) drip nozzle, (d1) diameter of cavity for filling 6.6 mm, (d2) diameter of capillary 1 mm 
The multi-well holder consists of a top and bottom part; between the parts a membrane 
adsorber stack or single sheet can be fixed. The top part of the holder has 96 cavities with a 
respective holding volume of 500 µl. Together with the fitting bottom part filtration chambers 
(wells) are formed. A transverse section of a well is 0.34 cm². The total amount of adsorbent 
per well can be set by the number of membrane layers. The sealing is performed by 
compression of the sealing surfaces. The form of the bottom part (permeate side) ensures a 
uniform flow distribution and a separate collection of permeates into the discrete wells. The 
bores form a funnel and then a capillary. This ensures an effective prevention of cross-talk 
between the wells. So the effective filtration area of each well is clamped in a contactless 
manner. The small diameter of the capillary ensures complete flushing and/or emptying of the 
fluid path. Driving forces for the permeation is a pressure gradient by vacuum or gravity. 
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Figure 8: 3D CAD construction of the 96-well membrane holder. By means of 7 threaded screws the 
membrane stack is compressed between the bottom and top part of the device. A uniform sealing is achieved by 
a criss-cross screwing with torque of 4 Nm. 
The non-destructive assembly of the device allows reuse. The holder is made from aluminium 
and can be heated up to 200 °C. It can be depyrogenated if it is necessary. Metal can bind 
molecules to their surface [65]. The holder was anodized to smooth the surface or avoid 
oxidation by caustics or acids. 
Since hydrophilic membranes are used, diffusion of aqueous solutions occurred due to 
capillary action leading to detrimental cross-talk which was caused due to the installation of 
dry membrane layers into the holder. To prevent this, the membranes were wetted with buffer 
before installation. In the following, the cross-contamination (cross-talk) between the wells 
was studied. In the first method dyes were used to stain the different membrane types under 
investigation. Due to the ionic interaction dyes like Ponceau S, Brilliant Black or Methylene 
blue were used. As the device accommodates various layers, the holder was equipped with a 
different number of layers. Each well was then filled with a staining solution. To exclude the 
influence of the residence time, the filtration started 15 min after filling each well. This 
selected time was higher than for the filtration where the residence time per well is less than 
1 min. Figure 9 demonstrates the absence of lateral diffusion i.e. no cross-talk. For easier 
addressing the loading of liquids, the 96-well holder was generally subdivided into an 8 x 12 
matrix (8 rows and 12 columns) for all subsequent studies. 
 
 
bolt
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Figure 9: Prove of absence of lateral diffusion. The membrane holder was equipped with a stack of 3 layers of 
anion exchange membrane (quaternary ammonium). Different volumes of a solution of Ponceau S (43.5 mg/L) 
in 20 mM Tris/HCl buffer (pH 7.4) were loaded into 40 wells. Left: The coordinates of the loading scheme 
describe the pipette volumes: A1-D1 400 µL, E1-H1 800 µL, E1-H1 1200 µL, E1-H1 1600 µL, E1-H1 2000 µL, 
E1-H1 2400 µL, E1-H1 2800 µL, E1-H1 3200 µL, E1-H1 3600 µL, E1-H1 4000 µL. The remaining well were 
filled with 500 µl water. The increasing load volume was chosen to visualize the breakthrough. After the holding 
time and filtration the membrane layers were removed and inspected. Layer 1 was on top. 
These previous results were no proof that non-binding small molecules like buffer 
constituents will as well not show lateral diffusion. Since phosphate ions are such a common 
component, a detection of this component was checked to exclude cross-contamination. The 
phosphate detection assay of Fiske and Subbarow [120] was employed, which is explained in 
the Appendix. If phosphate ions are present in a sample there will be a dark blue color change. 
Thus, different wells were filled randomly with a sodium phosphate solution, the remaining 
with water.  
 
Figure 10: Trial to detect cross-contamination using phosphate ions. Each well was filled with 500 µL water 
or sodium phosphate solution (0.16 mg/ml). The filtration was performed using a vacuum. Samples of the 
permeate were mixed with the detection reagent. The detection limit of the assay was 2 µg/ml. The blue 
coloration of the liquids and measurement of the absorbance at 820 nm indicate the presence of phosphate using 
the Tecan Safire Plate Reader. Blank was 564 ±58; sodium phosphate solution was 34948 ±245 arbitrary units. 
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After 15 min vacuum of 350 mbar was applied, the filtrates were collected and the presence of 
phosphate was checked. In the samples of neighbouring wells filled with phosphate buffer, the 
concentration of phosphate was below the detection limit (see Figure 10). The results 
presented were performed with three layers of membrane. 
 
4.1.2 Automation 
Aim of a high-throughput approach should be the processing of a plurality of samples with 
high statistical reliability. For the device described in the previous chapter an automated 
operation scheme was developed. The result of the development was a high-throughput 
downstream screening platform, suitable for an automated characterisation of membrane 
adsorbers. The structure and working principle of the platform is described in the following.  
The workstation was an automated liquid-handling platform coined Lissy 2002 from Zinsser 
Analytic [121]. Figure 11 shows the schematic top view of the system. For sake of clarity the 
moving needle arm or the gripper arm are emitted. The robot operates without a change of 
pipette tips: 8 pipetting needles are used and can be cleaned in a washing station. With these 
needles it is able to mix buffers and protein solution at small scale. A data import was 
programmed. The buffer compositions can be keyed into an Excel template, regarding 
species, conductivity, pH and concentration. Then the values are transferred to the control 
software of the liquid-handling platform and calculated by previously stored calibration 
curves. The stock solutions prepared by hand and are placed into the storage tanks. It is 
possible to mix up to 80 buffers in the tubes see Figure 11 (B). The filtration station to 
accommodate the 96-well membrane holder is located in the centre (see Figure 11). The 
commercially available vacuum station consists of a reception for depth-well plates to collect 
different fraction of the filtrate and a port to connect a vacuum pump (D). The membrane 
holder is placed on the top of the station. Furthermore, several stackers are used for depositing 
several depth-well plates and 96-well UV plates (F). A gripper arm is able to transport these 
consumables to different position (not shown). This includes the remove of the membrane 
holder or the transport of the 96-well UV plates to a connected 96-well plate reader.  
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Figure 11: The liquid-handling system. Schematic top view of the automated platform. (A) needle wash 
station, (B) falcon tubes for buffer mixing, (C) reservoirs for buffer stock solutions, (D) vacuum station, (E) 
deposition rack, (F) depth well collection plates, (G) 96-well UV transparent plates, (H) sample station, (I) 96-
well plate reader. A full processing cycle including the preparation of 80 buffers lasts 1-4 h (flow-through/bind 
and elute). 
The operation of the filtration station was modified to enable a processing with vacuum or 
pressure application. Before each filtration step a partial vacuum was generated by the 
vacuum pump. Filtration started when a defined pressure has been reached in the reservoir. 
The level of the applied vacuum influences the filtration rate. A valve was used to regulate the 
pressure of the compressed air during the filtration. A slight backpressure ≥ 5 mbar inside the 
filtration station was applied to prevent premature flow of the liquid by gravity force during 
the filling of each well.  
 
Figure 12: Circuit diagram vacuum station. (A) 96-well membrane holder, (B) vacuum device with 96-well 
collection plates each well with 2 ml capacity, (C) overflow protection, (D) pressure gauge, (E) pneumatic valve 
for vacuum application, (G) valve for pressure regulation, (F) pneumatic pressure valve, (H) vacuum reservoir, 
(I) pump, (J) compressed air supply. 
The sequences of the movement of the both arms described above can be programmed into an 
input mask displayed on the controlling computer. The program then performs the automatic 
execution of the chromatographic steps. A program structure is schematically summarized in 
Figure 13.  
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Figure 13: Screening program architecture. Through the user interface the individual chromatographic steps 
can be selected and the analysis steps controlled. The program structure is subdivided into 4 levels. Level 1 
consists of the user input. The sequence of steps and the assignment of loading schemes and buffer mixing 
recipes are implemented using Excel templates. Level 2 coordinates the final program sequence. Levels 3 and 4 
are sending the executing commands to the hardware. The individual programmed subroutines are named in the 
lower part of each level. 
The liquid-handling platform software ‘ZA runner’ then executes the programmed pipetting 
steps. 
 
4.1.3 Liquid-handling 
The critical factors using automated liquid-handling systems (LHS) are uptake (i.e. suction), 
transport, dispensing (delivering) of different liquids and cleaning of the needles [108]. 
Because air is compressible and its presence in the tubing would lead to erroneous results and 
the needles have to be cleaned after every pipetting step, all tubing and tips are always filled 
with water. Thus, during the uptake of liquids there would be a mixing of the sample with 
water. To prevent this, before sampling a certain amount of buffer and a small air bubble is 
picked up. This will remove residues of the liquid and create a barrier between the water and 
the sample. 
Furthermore, the speed of uptake and dispensing has to be carefully controlled. A too high 
speed of suction will lead to a destruction of the air bubble barrier. Additionally, during the 
sample preparation the pipetting of the protein solution is performed slower than for the other 
buffer components and is dispended directly in the sample liquid to avoid protein aggregation. 
The sampling of mixed buffers or collected fractions also is performed slower too. After each 
contact with a protein solution, the tips were cleaned by three successive steps of 5 ml water 
or detergent. The design of the wash station allows the rinsing of the outer surface of the 
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needles by immersing in flushing liquid. The different pipetting parameters determined for the 
experiments are summarized in Table 3. 
Table 4: Liquid-handling Parameter (LHP). The pipetting operations are divided into basic groups namely 
mixing in Falcon tubes, pipetting to the 96-well screening device and sampling. Level detection controls the 
movement of a tip down to the liquid surface before uptake or dispensing liquid, level tracking the associated 
movement. This is for keeping the exterior surface of the tip clean. Furthermore, it prevents the denaturation of 
protein due to shear forces (foaming). Then, the tips move to the predetermined position. A short delay after 
dispensing reduced drops, after uptake the fluid enters completely the tip. After the buffer addition into the 
respective receptacle the content is mixed by pipetting water at a high flow rate with the tips dipping into the 
liquid. The velocity affects also the stability of the protein and the accuracy of that pipetting step. A wash after 
each step is only necessary when the liquid or buffer is changed. During sampling it reduces deviations. 
LHP/ 
Step 
Variable Mixing 
buffer 
Mixing 
Protein 
Screening 
pipetting 
Sampling 
Uptake Immersion depth of pipetting tip [mm] 7 7 7 2 
 Liquid/air bubble before uptake [µl] 20/20 20/20 20/20 None 
 Uptake velocity [µl/s] 500 100 100 100 
 Level tracking / Liquid detection None Yes / yes Yes / yes None 
 Delay after receiving air/liquid [s] 0.2/0.5 0.2/1 0.2/0.5 0.2/0.5 
Dispensing  Immersion depth of pipetting tip [mm] 7 7 0 0 
 Dispensing velocity [µl/s] 500 150 150 150 
 Level tracking / Liquid detection Yes / yes Yes / yes Yes / yes Yes / no 
 Delay after dispensing 0.2 0.5 3 0.5 
 Forced wash after each step Yes Yes None Yes 
 
The accuracy of the pipetting depends on the diameter of the needle and tubing and the 
minimum step size of the piston pump motor. The manufacturer of the LHS specifies a 
standard deviation of less than 1 % per tip and < 3 % between all tips. The optimum working 
volume is 10 % of the syringe volume: this corresponds to 600 µl. In order to reduce the 
variations in the marginal boundary area, a volume correction factor (Volcor) was introduced 
Implementation of a 96-well HTPD platform 
28 
for each pipetting tip. With this the LHS software adjusted the number of motor steps to fit 
the actual amount of pipette volume to theoretical value. The adjustment was calculated by 
comparing the set point (seti) and actual value (actuali). The new volume correction factor was 
calculated by n measurements of the weight of a specific pipetting volume. The density was 
assumed to be 1 g/ml. The formula is given in (4.1) 
old
ni
i i
i
new Volcor
n
set
actual
Volcor 


1
1
       (4.1) 
The factor was determined for 50, 100, 300, 500, 800, and 2000 µl. For 5000 µl no factor 
could be evaluated due to limited motor steps. The selection was verified by typical pipetting 
volumes like sampling or filling the wells. Motor steps for a given volume between the values 
were calculated by linear interpolation.  
To determine the accuracy of pipetting steps in the area of typically used volumes during the 
operation, the actual amount of dispensed water of each needle was determined. The 
evaluation of pipetting errors later allows a differentiation between the deviation caused by 
the liquid-handling system, plate reader and membrane. Furthermore, the error accumulation 
could be estimated. Using the previous determined volume correction factor Table 10 in the 
Appendix (8.3.1) summarizes the characteristic values of the pipetting steps, i.e. the variation 
during the repetition of uptake and dispensing of each tip. As expected the volume correction 
factor and the variation increased for smaller volumes. 
The next issue of the liquid-handling procedure the filling of the wells was established. For 
screening different possible applications, a method was developed which allows each 
chromatographic step of a well to be defined independently. The described program structure 
was designed for use an Excel template sheet to enter the allocations of different 
chromatographic buffers and wells on the LHS, i.e. the 96-wells, the position of the 80 falcon 
tubes for the required buffer position and the volumes to be loaded. Furthermore, a calculation 
sheet for different buffer systems to adjust pH, conductivity and molarities of the buffers was 
established. The calculations are explained in the Appendix. 
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4.2 Screening of membrane adsorbers 
After the device and the working platform had been validated regarding installation, 
operational and performance qualification, the membrane adsorber screening platform had to 
be evaluated regarding the performance and influencing factors. The characterizations were 
done with stacks of three membrane adsorber layers. Thus, the membrane area per well was 
1 cm². This corresponds to a bed volume of 28 µL. This size is based on the typical binding 
capacity of the membranes adsorbers for model proteins [95, 122] and an appropriate loading 
volume per step. For avoidance of error accumulations the loading steps were kept small, i.e. 
the minimum volume per step was 400 µl because the necessary sample volume for the plate 
reader was 300 µL. Furthermore, due to the possible inhomogeneities of membrane adsorbers 
resulting in uneven ligand density three layers of membrane were used.  
 
4.2.1 Heterogeneity of membrane adsorbers on a small-scale format 
For a successful use of the 96-well membrane holder the deviation between individual wells 
must be small performing a chromatographic step under same conditions. An important factor 
is the deviation of membrane regarding ligand density and flow. Hence a trial was performed 
in which each individual well was run at the same chromatographic conditions. Bovine serum 
albumin and an anion exchanger with quaternary ammonium ligand were used for this model 
process. After conditioning and equilibration the same amount of protein solution was loaded 
into each well. Then a washing step and the elution were performed. The pressure was 
reduced to 300 mbar during the filtration steps. All fractions were analysed with the plate 
reader at 280 nm. After the measurement of the flow-through fraction of each well and 
calculating the binding capacity by subtracting from the added amount of protein the variation 
coefficient υ, the ratio of standard deviation σ to the arithmetic average μ, was determined, 
where n is the number of samples and Xi the measured value. The evaluation includes the 
variations caused by pipetting steps and analysis. 
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The calculation of the binding capacity BCFT per membrane area was done for each of the 96-
wells by  
 
A
Vcc
BC
LoadThroughFlowLoad
FT



       (4.3) 
Where cLoad is the concentration of the loading solution, cFlow-Through the concentration (mg/ml) 
of the sample, VLoad the loaded volume (ml) and A the membrane area (cm²). It is assumed 
that the volume of the flow-through fraction corresponds to VLoad. Furthermore, the binding 
capacity BCEl was determined by analyzing the elution fractions, whereas cElution is the 
concentration of the eluted protein (mg/ml), VElution is the volume (ml) and A is the area of 
membrane (cm²). 
A
Vc
BC ElutionElutionEl


        (4.4) 
Addition of the measurement of the wash fractions the recovery R was calculated by 
100




LoadLoad
ElutionElutionWaschWashLoadThroughFlow
Vc
VcVcVc
R
    (4.5) 
Where cWash and VWash are the amount and volume of protein in the washing. Table 5 
summarized the results. The similar values of BCFT and BCEl indicate a nearly complete 
elution of the bounded protein. 
Table 5: Evaluation of the variation of the measurement. Characteristic values using the 96-well membrane 
holder. 3 layers of an anion exchanger membrane with quaternary ammonium as ligand were used (1.03 cm² per 
well). After equilibration with 0.5 ml binding buffer (20 mM Tris/HCl pH 7.4), 2.6 mg/cm² of BSA were added 
in 2 steps of 0.5 ml each. The membrane was washed (0.5 ml) and protein was eluted by applying 1 ml of 1 M 
sodium chloride in binding buffer for determining the recovery rate. The amount of protein in the fraction was 
0.07 mg (υ=24 %). 
 μ σ υ 
BCFT  1.10 mg/cm² 0.05 mg/cm² 4.7 % 
BCEl 1.01 mg/cm² 0.07 mg/cm² 6.5 % 
R 100.6 % 3.2 % n. a. 
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To estimate the contribution of the membrane and 96-well plate holder to the variation 
coefficient, both pipetting errors and deviation of the plate reader must be included. Parallel 
preparation of 8 protein solutions as used for the loading experiments the protein 
concentration 2.66 mg/ml ±0.065 (2.4 %). The variance included mixing pipetting steps, 
sample pipetting and the deviation of the plate reader. Furthermore, the two loading steps, 
sampling and analyzing together with the membrane increased the variation coefficient to 
4.7 %. 
 
4.2.2 Influence of the flow rate on the binding performance 
It has been shown that the binding capacity of membrane adsorbers with quaternary 
ammonium IEX1 is independent from the residence time within a broad operational window. 
In contrast to larger-scale applications the flow rate using the screening device described here 
is higher, equalling to the residence time. In addition, during the experiments no uniform 
discharge of all wells was observed. Although the same pressure gradient was applied to all 
filtration chambers of the device during the filtration, different flow rates occur mainly due to 
the structure of the membrane or different viscosities of the filtration media.  
To determine the average flow rates of all wells at various differential pressures three layers 
of membrane were assembled into the membrane holder. To each well 500 µl buffer were 
applied. The choice of buffer conditions was chosen appropriate to the application. By the 
addition of sodium chloride the conductivity was increased for trials with the salt-tolerant 
anion exchanger IEX2. Several reduced pressure values down to -350 mbar were adjusted. 
The weight of flow-through in the depth-well collection plate was measured after filtration 
within specified times. The weight increase corresponds to the average flow rate. V is the 
flow rate, m the weight of the empty and m0 the filled collection plate and t the filtration time. 
96
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V
         (4.6) 
To compare the values with standard processes the residence time τ is represented by the 
inverse value of membrane volume per minute (FlowMV/min), where dM is the average 
thickness of the membrane and A the total assembled membrane area. 
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The flow rate depends on the type of membrane (Figure 14). Due to the matrix structure and 
the higher ligand density, the flows using the salt-tolerant anion exchanger are slower [122]. 
 
Figure 14: Flow rate depending on differential pressure. The flow rate was determined using the buffers 
20 mM Tris/HCl pH 7.4 for IEX1, for IEX2 150 mM NaCl 20 mM Tris/HCl pH 7.4. The ligand of the anion 
exchanger IEX1 was quaternary ammonium, for IXE2 it was polyallylamine. For each pressure value n=3 
measurements were performed. With an average thickness of 275 µm the flow rate at 350 mbar is 220 MV/min 
for IEX1 and 168 MV/min for IEX2. 
Compared to larger membrane adsorber devices, where the maximum operating flow rate 
typically is < 30 MV/min [27], the residence time is increased by a factor of 7 (IEX1) and 6 
(IEX2) using the 96-well filtration devices at -350 mbar. 
An additional approach was used to estimate the variation of the flow rate between several 
wells. 800 µl of 2.7 mg/ml BSA were applied to each well of the collection plates. 500 µl 
buffer was filtered through a stack of three membrane layers at 175 mbar differential pressure. 
The filtration process was stopped after 5 seconds.  
By analyzing the protein concentration in the flow-through fraction the calculation of the flow 
rate of individual wells was done with the formula 
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Where iV
  is the flow rate of an individual well, c0 the concentration of the BSA solution 
applied to the collection plate and ci the final concentration after filtration and t the filtration 
time. The coefficient of variation between individual wells was 50 %. 
To assess the effect of the residence time on the binding performance model systems were 
chosen to mimic several contaminants. The first test system was BSA. For simplification it 
was assumed that the average residence time of the test solutions were equal to the buffer 
used. This was assumed to all further investigations studies described in the following. 
 
Figure 15: Binding of protein depending on residence time. 3 layers of IEX1 or IEX2 were used (1.02 cm² 
per Well). Buffer for IEX1 was 20 mM Tris/HCl pH 7.4, for IEX2 150 mM NaCl 20 mM Tris/HCl pH 7.4. After 
equilibration with 2.0 ml buffer per well, for IEX1 1.0 mg/cm² of BSA were added in 2 steps of 0.5 ml, for IEX2 
2.3 mg/cm². Binding capacities were calculated for n = 12 wells for each residence time tested. 
Figure 15 showed that with increasing flow rate the binding capacity was reduced by 5 % for 
IEX1 and 14 % for IEX2. These effects could be explained in part by the structure of the 
membranes. In contrast to IEX1 the salt tolerant IEX2 consist of “ultra pores”, regions of the 
membrane with a dense structure [122, 123], in order to achieve a higher ligand density thus 
increasing the binding capacity. The loaded amount of BSA per membrane volume was 
chosen according to the expected binding capacity [95, 122], thus addressing all binding sites. 
The assumption is a reduced penetration into the “ultra pores” of IEX2 due to the short 
residence time, especially for larger molecules. 
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It was assumed that the behaviour was significantly higher for target substances with a high 
degree of contaminants needed to be removed (e.g. ≥ 99.9 %). Examples are viruses and 
endotoxins [33, 80, 84, 124-126]. Since working with pathogen viruses was not possible due 
to safety issues, phages were used instead as a model virus. The here used phage ΦX174 is 
described in Chapter 5.1. The concentration of infective virus particles is given in plaque-
forming units per volume (PFU/ml). The endotoxin solution was prepared by diluting a 
commercial available concentrate. Both detection assays are explained in the Appendix. In 
downstream processing the removal of contaminants can be expressed as Log Reduction 
Value (LRV). The value describes the ratio of the concentration of a molecule in the initial 
solution c0 compared to the filtrate ci.  

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LRV 0log
         (4.10) 
Figure 16 and 17 illustrate the influence of high flow rates on the removal of bacteriophages 
and endotoxin. It confirms the influence of residence time on binding of the virus particles. 
The same was true for the endotoxins which have phosphate as charged groups instead of 
charged amino acids in the case of ΦX174. The amount of phages or endotoxin in load was 
much lower compared to the maximum binding capacity of the membrane  
adsorber [88, 89, 122]. 
 
Figure 16: Binding of phages depending on residence time. 3 layers of IEX1 or IEX2 were used (1.02 cm² per 
well). Buffer for IEX1 was 20 mM Tris/HCl pH 7.4, for IEX2 150 mM NaCl 20 mM Tris/HCl pH 7.4. After 
equilibration with 2.0 ml buffer per well, 1.0 ml Bacteriophage ΦX174 spike solution was added in two portions. 
LRVs were calculated for n = 3 wells for each residence time. The initial infectivity titer was 1.2x10
7
 PFU/ml. 
0
0.5
1
1.5
2
2.5
3
3.5
4
4.5
0 0.005 0.01 0.015 0.02 0.025 0.03
Residence time [min]
L
R
V
IEX1
IEX2
Implementation of a 96-well HTPD platform 
35 
 
Figure 17: Binding of endotoxin depending on residence time. 3 layers of IEX1 or IEX2 were used (1.02 cm² 
per well). Buffer for IEX1 was 20 mM Tris/HCl pH 7.4, for IEX2 150 mM NaCl 20 mM Tris/HCl pH 7.4. After 
equilibration with 2.0 ml buffer per well, 0.5 ml buffer spiked with endotoxin was added. LRVs were calculated 
for n = 4 wells for each residence time. The endotoxin concentration c0 was 500 EU/ml. 
Although it has been shown that there are no diffusion limitations of mass transfer for 
membrane chromatography, two effects could explain the influence of short residence times 
on the binding as shown in Figure 15 – 17. The first is deterioration in the flow distribution of 
the 96-well device. A higher flow rate could lead to the formation of a flow profile in the 
center of each well. Thus, the throughput would be smaller at the edges of each well. Fewer 
binding sites would be available and the amount of non-bound molecules would increase. 
This assumption, however, was less favored due to the uniform staining of the membranes 
using Ponceau S shown in Chapter 4.1.1. An alternative effect could be the adsorption of gas 
as described in [127]. The binding mechanism could apply for proteins too. If a protein 
encounters a binding site, its energy is transferred to the surface of the adsorber or the mobile 
phase. A part of this energy also depends on the flow rate (kinetic energy). In the case of 
membrane chromatography, the binding interaction between ligand and molecules must be 
strong enough to overcome these forces and ‘slow down’ the molecule. The binding of a 
molecule can be induced by physical and chemical adsorption [128]. The chemical adsorption 
is a covalent bond with a small distance between the adsorber surface and molecule. For the 
reversible binding of proteins to a membrane, physical adsorption takes place, e.g. the van der 
Waals forces. These are characterized by broad reach and weak binding forces. The rate of 
adsorption depends on the time required to transfer the energy to the adsorber (adsorption 
probabilities). If the energy cannot be transferred, the molecule bounces back into the mobile 
phase. The probability increases with fewer available binding sites. This was also assumed for 
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the earlier breakthrough of molecules, even when sufficient ligands were available, because of 
the short residence time using 96-well plates. 
The results address the effect of residence time in these small scale formats, which is much 
higher than for the larger membrane adsorber devices. To minimize this effect a slight 
backpressure was used during the filling of each well. So the filtration process could be 
started simultaneously. Another possible operation was the use of a permanent vacuum during 
filling of the wells. However, it appeared that a permanent vacuum caused a shift in 
performance even when using the same chromatographic conditions for all wells. An 
explanation could be that the membranes in the individual wells fall dry with time. This 
changes the permeability for air and thus generates uneven the pressure drops over the plate. 
Consequently, the flow rates are reduced, especially during the filling of the last wells. Hence 
with time the resulting binding capacities increased (Fig. 18). 
 
Figure 18: Effect of filling the wells without backpressure. 3 layers of IEX1 were used (1.02 cm² per well). 
Buffer for IEX1 was 20 mM Tris/HCl pH 7.4. After equilibration with 2.0 ml buffer per well, 2 ml BSA were 
added in two steps (amount 2.5 mg/cm²). At a permanent differential pressure of 350 mbar column 1-12 were 
loaded sequentially using the 8 pipetting tips (A-H). The overall process time was 240 s. The binding capacities 
were calculated by analysing the flow-through fractions. 
 
4.2.3 Applications in high-throughput format 
This chapter specifically deals with applications of chromatographic methods using the HTS 
system. The most prominent application is the load of a substance to screen for appropriate 
binding, washing or elution conditions. Among others, this small-scale approach can be used 
for chromatofocusing. This technique separates proteins due to their isoelectric point [92, 93]. 
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For example, the protein is dissolved in buffers of different pH, e.g. stepwise 0.5 pH values. 
Using an anion or cation exchanger membrane the different protein containing solutions will 
be filtered through separate wells. By analysing the flow-through fractions the appearance 
indicates the region of the isoelectric point of the protein.  
A further refinement would be the analysis of protein mixtures or real process solutions. By 
analyzing the breakthrough fractions the separation of several substances can be evaluated. 
Furthermore, in bind and elution mode wash and elution steps could be improved by 
screening for conditions of separation different molecules or groups of proteins. This 
application and the interpretation of results are considered more in detail in Chapter 5. 
Another issue is the possibility to generate breakthrough curves and binding isotherms. This is 
feasible by selecting suitable load steps in 96-well format: an example is given in Figure 19.  
 
Figure 19: Example loading scheme for chromatofocusing and breakthrough curves. For 8 breakthrough 
curves the amount of loading volume would be increased, e.g., from 400 to 2000 µl. For chromatofocusing of 8 
proteins (A – H) the loading pH would be changed from columns 1 – 12. 
The breakthrough curve describes the time course of an adsorbent during the loading of a 
solution (feed) with a constant composition of molecules. The concentration gradient of the 
permeate is measured. In general, the breakthrough begins if the concentration of the 
molecule of interest in the permeate is > 0. Until then, the binding capacity corresponds to 
loaded amount. If the concentration c in the permeate corresponds to the initial concentration 
c0, the saturation of the binding sites is achieved (saturation). In advance of the saturation 
capacity, the dynamic binding capacity can be determined. This value puts the binding 
capacity in regard to the fraction of the permeate to the initial (feed) concentration. In 
chromatography is the determination of the dynamic binding capacity at 10 % breakthrough a 
typical benchmark for the performance (Fig. 20). 
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Figure 20: Generic breakthrough curve of a membrane adsorber. With increasing amount of loaded target 
molecule the saturation of the adsorber is achieved. The ratio of concentration in the permeate to feed tends to 1 
(static binding capacity). The ratio of 0.1 identifies 10 % breakthrough (dynamic binding capacity). 
The binding capacity behaviour BC (mg/cm²) of a membrane adsorber is described by  
dtcc
A
V
BC
BTt
t )(
0
0 

         (4.11) 
Where tBT is the loading time of the target molecule with the initial concentration c0 and ct the 
concentration in the flow-through at a particular time. The binding capacity depending on the 
load density of the target molecule is calculated by 
dVcc
A
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0
0 )(
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       ´
 (4.12) 
Where VLoad is the loaded volume of the target molecule solution with the initial 
concentration c0 and cFlow-Through the concentration of protein in the flow-through with the 
volume VLoad.  
At the level of the saturation the adsorption equilibrium is reached. In chromatography, 
isotherms describe the distribution of components between the stationary (membrane 
adsorber) and mobile phase (buffer). Among others, the maximum binding capacity as a 
function of the component concentration can be determined depending on various buffer 
conditions and additives. The adsorption equilibrium can be described by using various 
models. At sufficiently low concentrations non-linear isotherms can be approximated by 
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linear approaches following Henry, under assumption of infinite binding sites [129]. For 
chromatographic processes, however, the non-linear range is crucial as the most effective 
utilization of the adsorbent is to be achieved. The Langmuir isotherm is one model to define 
non-linear equilibrium reactions. Simplified assumptions are a reversible adsorption and no 
lateral interactions between different molecules and the formation of a  
monolayer [77, 86, 130].  
0
0max
1 cK
cKq
q



         (4.13) 
The binding capacity is described as follows: c is the concentration of the component in the 
mobile phase, qmax the maximum binding capacity, K is the equilibrium constant and q the 
existing capacity at equilibrium. K is the thermodynamic equilibrium of adsorption and 
desorption rate. By dynamically adding a sufficient amount of protein solution the equilibrium 
be achieved for breakthrough curves, c/c0 is then 1. This can be done with different 
concentrations and generates values for the calculation of the isotherms. In contrast to static 
methods like shaking the adsorbent in an e.g. protein solution, the dynamic filtration 
accelerates the process since the molecules reduces the binding sites faster [131]. 
 
4.2.4 Scalability of binding performance to larger devices 
A general problem in chromatographic applications is the transfer of the performance between 
different scales. This mainly concerns small-scale approaches. The scalability of the 96-well 
plates to larger devices has to be evaluated. In regard to different chromatographic conditions 
data for 96-well plates and for lab scale devices will be presented in the following. The MA15 
device consist of three layers membrane adsorber clamped into a polysulfone housing with a 
total membrane area of 14.9 cm² and a bed height of 0.8 mm. The void volume was 
determined with approximately 1 ml. 
A parameter often used to benchmark chromatography matrices is the binding capacity, 
expressed as the maximum binding capacity or capacity at 10 % breakthrough. Buffer 
composition, flow rate and protein concentrations have influence on the adsorption kinetics 
and equilibrium. In general, these effects are unknown for the given system i.e. adsorber and 
target when starting a screening. The following example illustrates the issue. Different buffer 
compositions are applied to find binding conditions with high capacity for a certain 
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contaminant. A fixed amount of protein (load) is filtered at these conditions. The binding 
capacities are calculated from the mass balance of the initial concentration and flow-through 
fraction in each well. From the calculated capacities one cannot deduce whether the 
adsorption equilibrium is reached. Figure 21 illustrates the situation for several breakthrough 
curves. Running only a single loading does not enable finding the maximum binding capacity 
at a given buffer condition. 
 
Figure 21: Schematic breakthrough curves at different buffer conditions. IEX2 was built in an MA15 
device with 3 layers and 15 cm² membrane area. Three runs were performed at different buffer conditions. The 
saturation of the membrane is achieved at different amounts of protein applied (load density). At given values of 
load the breakthrough value c/c0 differs. If the breakthrough is determined only at a fixed load no statement 
about the saturation of the membrane can be made. 
Taking into account the issues discussed above and the fact that the residence time using  
96-well plates is much lower than in larger devices, the scalability of maximum binding 
capacity has to be addressed critically. Commercially available anion exchange 
chromatography devices have been used to evaluate the scalability of binding capacity. The 
binding capacities of the two systems were compared under equal protein concentration, 
buffer conditions and amount of protein loaded per membrane volume. The calculation of the 
binding capacity using MA15 is described in the Appendix, for the 96-well plates a modified 
formula 4.3 was used (4.14). To increase the precision of the determination of the void 
volume VV of the 96-well membrane holder was inspected more closely. The permeate side 
had a hold up volume of 46 µl. Because of a very low bubble point of the membrane below 
0.3 bar this volume was always still filled with liquid after the equilibration and loading steps. 
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a  
b  
Figure 22: Comparison of protein binding. Both devices had 3 layers of IEX1 (a) or salt-tolerant IEX2 (b). 
Buffer was 20 mM Tris/HCl pH 7.4. Using the automated buffer mixing procedure, different concentrations of 
phosphate were added to the buffer and protein solution as indicated in the figures. After equilibration with 
2.0 ml buffer per well, 2.0 mg/cm² of BSA were added in 2 steps of 0.5 ml each. For a direct comparison the 
same types of membranes assembled into a MA15 device with 3 layers and 15 cm² membrane. The loading 
volumes were normalized to the membrane area. 
The difference between the two graphs could be explained by the influence of the factors 
described above. Furthermore, differences due to fluctuations in the production of different 
membrane lots could not be excluded. Nevertheless, a clear trend for both membrane types is 
evident. In Figure 23 the scalability of the relative values is presented.  
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a  
b  
Figure 23: Comparison of relative values in protein binding. The data from Figure 22 are compared relative 
to the maximum value for each IEX (a: IEX1, b: IEX2). 
The data are generated under conditions of overloading. That means less binding sites were 
available to bind all molecules. The breakthrough is > 0 and the loading reaches the 
adsorption maximum.  
In further trials the binding properties of phage ΦX174 have been investigated. In this case 
the amount of free binding sites in the adsorbing matrix exceed the amount required for 
binding the phage particles several fold as confirmed in the Appendix (8.2.7). The results 
show comparable relative values at different buffer conditions for both devices (Fig 24 + 25). 
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a  
b  
Figure 24: Comparison of phage binding. Both devices were equipped with 3 layers of IEX1 (a) or IEX2 (b). 
Buffers (20 mM) were at pH 4: NaAc, pH 6: BIS-Tris, pH 8: Tris/HCl and pH 10: CHES. Using the automated 
buffer mixing procedure, different concentrations of phosphate were in the buffers and protein solutions. After 
equilibration with 2.0 ml buffer per well, 2.0 ml of phage solutions were added. The initial infectivity titer was 
1.5x10
7
 PFU/ml. For comparison the same types of membranes were built-in a MA15 Device with 3 layers and 
15 cm² membrane. The loading volumes were normalized to the membrane area. The absolute LRVs were 
compared with the maximum value for each membrane. 
In the following the scalability of protein binding depending on the loaded amount of protein 
using the 96-well membrane holder in comparison with a larger device is shown. As 
previously discussed, the short contact time generates earlier breakthrough. 
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a  
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Figure 25: Comparison of the breakthrough behaviour. Both devices were applied with 3 layers of IEX1 (a) 
or IEX2 (b). Buffer was 20 mM Tris/HCl pH 7.4. The breakthrough behaviour is described as the ratio of the 
amount m of protein in the flow-through to the loaded amount m0. The breakthrough curves with MA15 devices 
were determined using an ÄKTA FPLC system described in the Appendix. The flow rate was 15 ml/min 
(3 MV/min). For both experimental setups the initial BSA concentration was 1 g/l. The amount of protein in 
flow-through of the 96-well plates was analysed by measurement of the concentrations of BSA. The loading 
scheme was similar to Fig. 19. For a load volume > 2 ml the fractions were pooled before measurement of the 
concentration in the flow-through. 
The data show the scalability of relative values from 96-well to the MA 15 devices. Due to 
the influencing factors and the errors due to small working volumes the transfer of absolute 
values from 96-well to larger scales is limited. 
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4.3 Conclusion 
The first part of the thesis dealed with the problematic of needed improvements regarding 
time and material consumption and the investigation of complex process steps in 
chromatographic applications using membrane adsorbers.  
The development of a 96-well membrane holder [125] simplified the incorporation of 
modified membranes and the evaluated liquid-handling system enables the parallel processing 
of a large number of small samples of buffers and protein solutions. The three membrane 
layers used in this study, respectively the membrane area per well lead to optimized material 
consumption, required sample size and improve process stability. 
The screening applications presented here highlighted critical factors to be considered during 
operation. An optimized setting of liquid-handling parameters and work flow reduced the 
possible error. In spite of the potential heterogeneity of the pore structure and ligand 
distribution of the membrane, a negligible standard deviation in the well-to-well comparison 
was observed. A limited scalability from 96-well formats to larger devices has been shown. 
The loading amount is critical when scaling the membrane to larger devices, e.g. to determine 
the maximum binding capacity the saturation of all binding sites have to be assured by 
loading a sufficient amount of protein to a well. In particular, the high and limited controllable 
flow rate is of most importance. Different model systems have confirmed the assumption that 
higher flow rates cause a considerable increase the passage of protein molecules passing the 
membrane. This was especially true for very small amounts of protein in the breakthrough. 
However, it was confirmed that the relative ratios between different buffer conditions can be 
scaled up. 
The establishment of a high-throughput screening system for membrane chromatography 
leads to new scopes of operation. Due to the high degree of parallelization it was possible to 
perform a high number of experiments compared to conventional fast protein liquid 
chromatography which would not allow such a high resolution of influencing factors on a 
broad range. The use of a statistical experimental design can reduce the experimental effort 
further. However, this will increase the risk of failing to spot interactions between involved 
factors by necessarily reducing the generated data. 
After the establishment of the screening system, in the next chapter the investigation of anion 
exchanger membrane adsorbers for the separation of contaminants from the target molecule 
was performed. 
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5 Investigation of contaminant removal using anion exchanger 
membranes at various process conditions 
Chapter 4 of this work focused on the development of an automated HTS system. This 
platform now has been used to characterize the contaminant removal by using positively 
charged membrane adsorbers. Due to the previously limited available small scale approaches, 
published studies are often limited regarding the investigation of the binding performance of 
membrane adsorbers using a large number of buffer conditions. The studies often considered 
only a small number of conditions in a small operational window. Furthermore, due to 
different properties of the used model or process solution like concentration and purity, 
various process parameters like flushing volumes or flow rates and analysis also a comparison 
of data from different publications is limited. Therefore another aim of this thesis was a 
systematic evaluation of the binding performance of anion membrane adsorbers under strictly 
comparable buffer conditions. Influencing factors on the binding and separation performance 
have been evaluated. Model systems consisting of single or multiple proteinogenic 
components were used. The selection of buffer conditions was based on preliminary results 
and published data. Furthermore, the thresholds of common process conditions for anion 
chromatography were considered.  
Previous results have been shown that especially due to the dependence on the residence time 
the comparison in binding of 96-well to larger devices is somewhat limited. Therefore, the 
focus was on the interpretation of relative changes of binding performance due to the buffer 
conditions which were investigated. 
 
5.1 Model systems for studying chromatography in downstream 
processing 
The understanding of the mechanisms of contaminant removal by chromatography media 
during the purification in downstream processes requires reproducible model systems to 
mimic real process solutions. The use of real process media does not necessarily generate 
more meaningful data for analysis, due to a more complex composition of the medium and 
interactions of components which can adversely affect the interpretation of results. Using the 
same cell line for different products is preferred for the production process. The genetic 
information of the master cell line is only slightly modified to express a specific target 
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molecule. For example, in mAb production based on the same cell line it has been shown that 
the purification performance of a chromatographic step varies for various  
antibodies [110, 133]. Small variations during repeated cultivations can change the 
composition of HCP or the amount of target protein. Factors like stability due to the storage of 
real process media or buffer exchange have to be controlled carefully. These issues can be 
reduced by using model systems. Also process development approaches with model systems 
are described. A common method is the use of spiking solutions, for example, containing 
viruses or endotoxins for contaminant removal studies [59, 84]. Depending on the purity of 
the spike solution, further contaminants can be introduced into the process media due to the 
incomplete purification of the virus spike.  
Within this thesis the approach was to establish model systems. It was assumed that 
knowledge of these processes can later be transferred and compared to real processes. The 
chosen molecules, which have been used, are presented in the following. 
The production and use of infectious viruses as a model is complicated, time consuming and 
associated with safety concerns regarding the health risk of the operators [93, 134]. Therefore, 
bacteriophages are an accepted alternative as a model system with several advantages: They 
can be produced in microbial organisms with short cell cycles like Escherichia coli C (E.coli) 
and are generally harmless to humans because they infect only bacteria. Disadvantages are 
that phages are smaller than most viruses and have different surface proteins, which can affect 
the binding to an adsorbent. Nevertheless, several studies have shown the comparability to 
viruses and support the use of bacteriophages as appropriate model viruses [84, 95]. For the 
investigations presented here phage ΦX174 was used. Other commonly used models are PP7 
and PR772 [93]. The icosahedral shaped bacteriophage ΦX174 has a diameter of 25-
30 nm [135, 136]. The isoelectric point pI is reported between 6.4 and 6.7 and has a thin 
protein coat covering a nucleic acid core [135, 137]. It does not have a lipid envelope. It 
consists of 26 % nucleic acid [135] and, furthermore, has a protein density of 1.4 mg/ml [93]. 
The phages were produced by infection of cultivated E.coli cells. Production and spike 
preparation is described in the Appendix. 
Host cell proteins are perhaps the most inhomogeneous class of impurities. Different 
components were described in different cell cultures. Often used Chinese hamster ovary 
(CHO) cell lines were studied regarding the composition of HCP by Jin, M. et al. [138]. The 
distribution in terms of molecular weight and pI was shown. The largest proportion of HCP 
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had a pI between 5 and 6, most proteins had a molecular weight between 25 and 75 kDa. 
Similar measurements were performed by Matthias Kraetzig during his Master thesis [139]. 
The analysis using two-dimensional gel electrophoresis identified proteins with a molecular 
weight of 25 to 60 kDa. Due to similar distribution of HCP in real process solutions regarding 
pI and size, several commercially available proteins can be used to mimic HCP solution. 
BSA, lysozyme, myoglobin, ovalbumin, conalbumin, cytochrome c and chymotrypsinogen 
were described as well-fitting model proteins [78]. In the work presented here BSA and Green 
Fluorescent Protein GFP were used as model systems. BSA has a pI of 4.7 and a molecular 
weight of 66.4 kDa [63, 100], it binds to anion exchangers at neutral pH. This also applies for 
GFP with a pI of 5.8 and 29 kDa. GFP was chosen to mimic a smaller HCP. Furthermore, the 
advantage of the protein was the simpler analysis by measuring its fluorescence. The 
calibration curve displayed in the Appendix confirms a possible detection even in minute 
quantities. Additionally to the use as contaminants, these proteins can also mimic a target 
molecule during the process development. 
Likewise to HCP, the molecular weight of host cell DNA can have a broad range. The size of 
DNA and fragments are expressed as the number of its base pairs (bp). Salmon sperm DNA, 
with a MW of approximately 1000 bp, was used as a smaller; calf thymus DNA with a MW 
up to 24000 bp was used as a larger model contaminant. To evaluate the endotoxin removal, 
the Limulus Amebocyte Lysate test was used as described in 8.2.6. It is derived from the 
blood cells of Limulus polyphemus, the Atlantic horseshoe crab [140].  
In general, these individual components can be used systematically to characterize adsorptive 
materials. This applies to the use individually, as well as a mixture of some or all components. 
From the generated data, information about the performance of adsorbers like binding 
capacity, recovery and reuse after cleaning can be drawn. From this, it may be possible to 
transfer the results to real process solutions. This necessitates the right choice of model 
systems. 
 
5.2 Experimental design and evaluation of results 
The high-throughput screening approach requires the planning and evaluation of appropriate 
tests. For the investigation of a large number of process conditions a statistical design of 
experiments can be used. The principle behind is to reduce the number of measurements and 
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for experiments to determine influencing factors. The selection of the chosen experimental 
conditions and representation of results has been explained in this section. 
The necessary numbers of measurements e depends mainly on the number of variables k like 
pH or conductivity in chromatography. The different setpoints nv for each variable affect the 
effort. 
k
v
ne             (5.1) 
Often nv > 2 is required to minimize to the loss of information or to use non-linear regression 
models. Thus, the number of trials grows faster than the number of variables. Therefore, using 
a reduced experimental design reduces the effort, like the central composite design or the 
Box-Behnken design. A disadvantage of the concept of experimental designs, investigating a 
large number of variables with only few measurements, is the risk of misinterpretation of the 
data or a low amount of evidence [108]. The evaluation of the experimental design can be 
determined via the power, depending on the signal-to-noise ratio. Noise is designated as the 
standard deviation. Signal is defined as the smallest change of a target value, like binding 
capacity, recovery or separation in chromatography. Effects can be determined using 
mathematical relationships to represent correlation. Significant factors are ascertained from 
variance analysis like one-way-ANOVA [141, 142]. 
The advantage of the high-throughput approach is the possibility to run a high number of 
experiments parallel. The experimental designs selected in this thesis were based on existing 
knowledge from previous experiments. These included the known conditions for 
chromatographic steps in downstream processing or the isoelectric point of proteins. Thus, the 
density of data points for conductivity in known condition areas was higher than in the border 
areas of possible applications. The pH was set around 7. This is one common setpoint in the 
purification of monoclonal antibodies by ion exchanger chromatography, e.g. to prevent 
aggregation [9, 64, 65]. 
Large data sets require the use of a presentation that allows visual interpretation with 
programs for statistical analysis. The dependence of a target value from two parameters can 
be presented by three-dimensional plots. For the sake of clarity, the three-dimensional plot is 
transformed into a two-dimensional contour plot. The target value is mapped using a color 
gradation. This form of presentation was preferred in this thesis. The color surfaces between 
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the individual checkpoints were determined by a linear interpolation (for the algorithm used 
see the Appendix).  
 
Figure 26: Example of a contour plot. The target value depends on influencing factors A and B. Conversion of 
the three-dimensional plot (left) into a contour plot (right). Black dots mark measured data. The target value is 
mapped using a color gradation. In this example the target value only depends on factor A. 
Nevertheless, this kind of presentation is limited to three dimensions. Extension to four 
dimensions by a three-dimensional plot and combination with a color gradation lead to 
unclear arrangements of data. For the presentation of more influencing factors and target 
values, several contour plots can be combined. Sweet spot analysis considers the different 
variables in downstream processing. These are a superposition of several contour plots. In 
purification using chromatography yield and the amount of contaminants like aggregates, 
DNA and HCP are of interest. Figure 27 shows a sweet spot analysis. It displays the 
knowledge area, control space and design space of a process [96, 143, 144] in a single figure. 
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Figure 27: Example of a sweet spot analysis. Factors A and B affect both the yield of target and DNA removal 
of a purification step (upper part). By superposing of both charts the preferred working area is determined. 
Knowledge space includes the investigated process conditions. In the sweet spot, also known as the design space, 
the necessary conditions for that step are contained. The control space is located within this design space. The 
control space specifies the acceptable limits for the influencing parameters A and B during this process step. 
This method enables the inclusion of several variables into the analysis. 
Sensitive methods for the analysis of trace concentrations of contaminants are used in DSP. 
Assays based on enzymatic reactions are particularly sensitive and easy to disturb e.g. the 
dependence of the endotoxin detection assay on pH and proteins [58]. The PicoGreen assay 
for the detection of DNA is distributed by components like BSA. To circumvent this, 
appropriate assays have to be used or complex multivariate calibrations are necessary [145]. 
In this thesis different approaches have been used:  
- Model systems whit only a single component 
- Mixed-model solutions with different assays, wherein the detection method for a 
component was negligibly affected by the others 
Knowledge 
space
Sweet spot / 
design space
Control space
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A further approach was the analysis by comparing concentrations of the initial feed solution 
and the permeate. Based on the assumption of the identical effect of the buffer the 
breakthrough was calculated. An example was GFP, whose fluorescence depends on the pH 
value [146]. With a constant pH, the breakthrough of the component could be determined in a 
broad concentration range. 
 
5.3 Binding performance of anion exchanger membrane adsorbers 
Due to binding capacities and very high flow rate, membrane adsorbers are particularly 
suitable for final purification steps (polishing) where only small amounts of contaminants are 
present. Since typically anion exchangers are used, the knowledge regarding performance and 
interactions is important. Membrane adsorbers containing quaternary ammonium ligands have 
already been studied to some extent. Besides them, salt-tolerant anion exchangers are 
particular of interest. They bind biomolecules at higher salt concentrations or conductivities. 
Before the anion exchanger step, the conductivity of protein solution has often to be adjusted. 
A major advantage of salt tolerance is the reduction of buffer needed, because no or less 
dilution is necessary. A lower dilution i.e. smaller process volume also reduces the time for 
subsequent concentration after the chromatographic step in flow-through mode [33]. 
 
5.3.1 Influences of salt and pH on the binding of model contaminants 
Generally, electrostatic interactions are responsible for binding of molecules to ion 
exchangers. The binding performance is strongly affected by the presence of salt, the pH-
value and the isoelectric point of the present molecules. However, further mechanism like 
weak hydrophobic interactions or mutual influence of components can affect the performance 
of an anion exchanger [94, 147, 148]. So the first part of the evaluation of contaminant 
removal using membrane adsorbers the performance of anion exchangers at the binding of 
single model molecules were performed. Factors were pH, mono- and multivalent salts. In 
contrast to monovalent, multivalent salts consist of more than one electron to form an ionic 
bond with another molecule. It has been found that multivalent salts can induce effects on 
proteins like surface charge inversion [149] and affect the separation of proteins. It was 
expected that these effects could also be of interest for the purification in downstream 
processing using membrane adsorbers. Differences between the interactions of contaminants 
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with both anion exchanger membranes should be examined. For all screening experiments the 
96-well membrane holder consisting of 3 layers of membrane were used. The pressure was 
reduced to -350 mbar. 
The first trace impurity studied was the phage ΦX174. It was kindly donated by the R&D 
department at Sartorius Stedim Biotech GmbH. The preparation is described in the  
Appendix (8.1.6). The salt tolerance of IEX2 was particularly shown using this model 
contaminant. The detection limit was determined to be LRV 5. The results are shown as 
contour plot in Figure 28. 
 
Figure 28: Influence of NaCl and pH on the binding of phages. Buffers for each IEX were 20 mM sodium 
acetate at pH ≤ 5.5, 20 mM BIS-Tris at pH 6.5 and 20 mM Tris at pH ≥ 7.5. Equilibration was done with 2.0 ml 
buffer per well. 3 parallel samples were pooled for each data point before phage detection using the infectivity 
assay. The initial infectivity titer was 1.5x10
7
 PFU/ml. 1 ml phage solution was added at each condition. 
Gradation of the color scheme is LRV 0.5. 
While the LRV of IEX1 was already close to zero at a sodium chloride concentration of 
100 mM, IEX2 still retained phages up to a conductivity > 50 mS/cm i.e. > 500 mM. For both 
IEX the binding was decreased at lower pH. IEX2 still bounds phages near the isoelectric 
point. This may be an indication for a further separation mechanism like slight hydrophobic 
interaction or that there is still sufficient interaction between the ligand and remaining 
negatively charged surface proteins of the phages. It is described that primary amines take 
both electrostatic and hydrogen bond interactions [94]. This enhances interaction between 
ligand and target and is also rated as the reason for the salt tolerance.  
The next contaminant investigated was endotoxin. The binding was checked in the range of 0 
to 500 mM sodium chloride and a pH range from 6 to 9. The pH was limited because both salt 
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and pH are inhibiting the enzymatic detection reaction. The binding performance was 
calculated according to equation 4.10. The detection limit was determined to be LRV 4. 
 
Figure 29: Influence of NaCl and pH on the binding of endotoxin. Buffers for each IEX were 20 mM BIS-
Tris at pH ≤ 7 and 20 mM Tris at pH ≥ 8. Before equilibration each well was sanitized with 2 ml 1 M NaOH. 
Equilibration was done with 2.0 ml buffer per well. 12 different conditions were tested: three parallel samples 
each. 0.5 ml was added with a concentration of 500 EU/ml at each data point. Gradation of the color scheme is 
LRV 0.5. 
Before using the 96-well membrane holder it was depyrogenized at 200 °C and the membrane 
was sanitized with sodium hydroxide. The results are shown as contour plots. Both 
membranes were able to remove the endotoxin over a broad operational range. The endotoxin 
is a lipopolysaccharide which consists of a lipid moiety and a polysaccharide that can contain 
phosphate groups. Responsible for the binding of endotoxin are the interaction between the 
negative charged phosphate groups of the protein structure and the positive charged ligands of 
anion exchanger media. Furthermore, it was mentioned that there are probably hydrophobic 
binding between the adsorbent and lipophilic groups of endotoxin too [59]. The log reduction 
level LRV was higher for IEX2. This membrane bound > 99 % of the endotoxins, even at 
higher salt concentrations. The lowest LRVs were found at pH 6 (LRV 2). The salt tolerance 
increases for higher values up to pH 9. IEX1 was more sensitive to higher salt concentrations, 
between pH 7 – 8 > 50 mM which correlates to published data [84]. The screening showed 
favored buffer conditions for endotoxin removal at higher salt concentrations around pH 7, 
where the endotoxin removal was still > 99 %. At higher pH-values and salt concentrations 
the LRV was below 2. 
The binding of small salmon sperm and large calf thymus DNA to IEX1 and IEX2 has been 
examined. Sodium chloride was used to generate higher conductivities. Depending on the pH, 
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appropriate buffer systems were used to ensure a sufficient buffering. The load concentration 
was 100 ng/ml. The concentration of DNA was measured by the PicoGreen Assay. The 
performances of binding the contaminant at different conditions were evaluated by calculating 
the removed amount of DNA. The 96-well plate was fully exploited: 24 conditions were 
tested, each using four parallel samples. 
 
Figure 30: Influence of NaCl and pH on DNA binding. Buffers for each IEX were 20 mM sodium acetate at 
pH ≤ 5.5, 20 mM BIS-Tris at pH 6.5, 20 mM Tris at pH 7.5 – 8.5 and CHES at pH 9.5. Equilibration was done 
with 2.0 ml buffer per well. For each tested data point concentration was 100 ng/ml. 1 ml DNA solution was 
added at each condition. Gradation of the color scheme is 10 %. 
The high affinity of DNA due to the negative charge caused a consistently good binding to the 
membrane. There was no significant difference in the removal of DNA at the different pH 
values tested. IEX1 showed a slightly higher breakthrough of the smaller Salmon sperm 
DNA. For all conditions the DNA concentration in the flow-through fraction was below the 
range of the calibration, where the lowest value was 10 ng/ml. The salt-tolerant IEX2 also 
showed no breakthrough at higher conductivities.  
The presented results confirm trends due to buffer conditions, which were also described in 
the literature for other ion exchanger media [17, 84]. The amount of contaminants loaded was 
always much smaller than the binding capacity for that kind of molecule. Therefore the 
binding of BSA was investigated depending on the pH. The loaded amount of protein 
exceeded the maximum binding capacity of the installed membrane area. 
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Figure 31: Influence of NaCl and pH on BSA binding. Buffer for each IEX was 20 mM Tris at pH. The pH 
was adjusted using HCl. Equilibration was done with 2.0 ml buffer per well. For each tested data point 4 parallel 
samples were analyzed. The amount loaded of BSA was 2.8 mg/cm². 1 ml BSA solution was added at each 
condition. The concentration of BSA was measured at 280 nm. Gradation of the color scheme is 0.2 mg/cm². 
As expected, the binding capacity of IEX2 was higher than that of IEX1. The capacity of 
IEX1 slightly increased with higher pH. BSA was less bound for IEX2 at higher pH in 
combination with an increasing salt concentration. It was assumed that the loss of total 
binding capacity is caused by the reduction of protonated polyallylamine. Holmes-Farley et 
al. found that the protonation of polyallylamine will be reduced at pH > 8. Furthermore, they 
mentioned that at pH < 7 the ligand preferably appears as monoanion which also may reduce 
the binding forces [150].  
In the following, the effect of multivalent ions on the binding behavior of BSA, GFP and 
DNA was investigated. Various amounts of phosphate or citrate buffer with the same pH were 
added to the basic buffer. Figure 32 shows the effect of sodium phosphate on the binding of 
Salmon sperm DNA to both ion exchanger matrices. Results are shown as contour plots. 
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Figure 32: Influence of phosphate and pH on DNA binding. Buffers for each IEX were 20 mM BIS-Tris at 
pH 6 – 7 and 20 mM Tris at pH 8. Equilibration was done with 2.0 ml buffer per well. 3 parallel samples were 
analyzed for each tested conditions. The load density of DNA was 140 µg/cm². 1 ml DNA solution was added at 
each condition. The concentration of DNA was measured at 260 nm. Gradation of the color scheme is 5 µg/cm². 
IEX1 was less affected by multivalent salt than IEX2. This showed that IEX2 is less tolerant 
towards multivalent ions. Nevertheless, also at higher concentrations of sodium phosphate 
binding of DNA occurred. As seen with BSA, the binding was reduced at higher pH values. 
A noticeably binding of DNA at higher phosphate concentrations lend the interest to protein 
binding under such conditions. The binding of BSA was investigated over a broad range of 
pH and with different multivalent salts to detect differences to the removal of DNA. Both runs 
with phosphate and citrate were performed simultaneously testing 32 conditions at once. The 
results are shown as contour plot. 
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Figure 33: Influence of phosphate, citrate and pH on binding BSA IEX1. Buffers were 20 mM BIS-Tris at 
pH 6, 20 mM Tris at pH 7.5 and 20 mM CHES at pH 9. Equilibration was done with 2.0 ml buffer per well. 3 
parallel samples were analyzed for each tested conditions. The load density of BSA was 2.6 mg/cm². 1 ml BSA 
solution was added for each tested conditions. The concentration of BSA was measured at 280 nm. Gradation of 
the color scheme is 0.1 mg/cm². 
Both mono- and multivalent salts reduced the binding performance of IEX1, while 
multivalent ions had a greater effect. Citrate decreased the binding more than phosphate. 
Furthermore, a higher pH increases binding with respect to the operational window. In  
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Figure 34 the results are summarized for IEX2. In contrast to IEX1, multivalent salts decrease 
the binding while the monovalent sodium chloride showed no significant effect. Furthermore, 
at a pH of 6 and 9 a slightly increased conductivity affected the binding of IEX2 positively.  
 
 
 
Figure 34: Influence of phosphate, citrate and pH on binding BSA IEX2. Buffers were 20 mM BIS-Tris at 
pH 6, 20 mM Tris at pH 7.5 and 20 mM CHES at pH 9. Equilibration was done with 2.0 ml buffer per well. 3 
parallel samples were analysed for each tested conditions. The load density of BSA was 2.6 mg/cm². 1 ml BSA 
solution was added at each condition. The concentration of BSA was measured at 280 nm. Gradation of the color 
scheme is 0.2 mg/cm². 
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A similar effect of phosphate was observed for low-concentrated protein with a pI in the same 
range like BSA. Green fluorescent protein at a low level of 1.6 µg/ml was loaded to the 
membranes at different conditions. The concentration was determined with the BCA reagent 
and expressed as BSA equivalents. 
 
Figure 35: Influence of phosphate and chloride on GFP binding. Buffer was 20 mM Tris at pH 8. 
Equilibration was done with 2.0 ml buffer per well. 3 parallel samples were analysed for each condition. 1 ml 
GFP solution processed at each condition. Gradation of the color scheme is 10 %. 
Both membranes retained the protein at low salt concentrations. Similar to the observations 
with BSA at a high load density, the effect of phosphate was much higher than chloride for 
IEX2. Thus, the binding behavior for phosphate > 10 mM and chloride > 200 mM differed 
and confirmed a significant difference between both anion exchangers. 
Due to the large differences in binding capacity of IEX2 caused by the addition of multivalent 
salt ion, it is as apparently disadvantage of that type. In general citrate or potassium phosphate 
buffers reduce the purification power of these anion exchange membranes. However, it was 
assumed that this effect can be used for the separation of molecules. 
 
5.3.2 Effect of mono- and multivalent salt on the separation of molecules 
The previous result made the approach feasible to separate molecules by using multivalent 
salt ions without a strong increase of the conductivity. This could be an advantage in a 
purification scheme. The possibility was investigated using several model systems, which 
consist of at least two components. The performance of the membrane for separation a protein 
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mixture was evaluated by the selectivity S. It was calculated by the ratio of the breakthrough 
of target molecule BTtm and contaminant BTcont.  
cont
tm
BT
BT
S 
          (5.2) 
The minimum breakthrough value was defined as the lower detection limit. A high value for 
selectivity identifies preferred binding of the contaminant while the target molecule passes the 
membrane. If the selectivity << 1, the target molecule will be preferentially concentrated at 
the adsorbing media. Thus, the bind and elute mode is suitable for purification process. 
Process parameters, which ensure a high selectivity, however do not represent the most 
efficient operating conditions. Besides to selectivity the yield has to be as high as possible. If 
the removal of a contaminant is e.g. almost 100 % but also 20 % of the target molecule 
remains on the adsorbent, yield is not sufficient. The yields in the following experiments were 
given by the breakthrough of the target molecule calculated from the equal volumes of the 
load and permeate. Assuming that the capacity limit for a certain contaminant was not 
reached, a higher load can further improve the yield. Furthermore, studies have shown a 
displacement of target molecules by contaminants during a loading step [110]. The higher 
affinity of the contaminant for the binding sites displaced already bound molecules. 
As a purification model process the removal of DNA from a mixture with GFP in flow-
through mode was evaluated. The aim was to determine the conditions where the target 
molecule GFP passes the membrane whereas the DNA is retained. Due to their pI both 
components are negatively charged and interact therefore with positively charged anion 
exchanger. The DNA was measured photometrically at 260 nm; GFP by its fluorescence at 
509 nm. The concentration of GFP was so low that the analysis of the DNA was not 
significantly affected. Conversely, the DNA showed no influence on the fluorescence. The 
separation of both components was examined in the range of pH 6 to 9, a sodium chloride 
concentration of 0 to 650 mM and a phosphate concentration up to 30 mM. The fluorescence 
of GFP depends on the pH [146] and was investigated in the Appendix. The results for pH 8 
are shown in Figure 36. The minimum considered breakthrough value was 5 %; the maximum 
95 %. Thus, the maximum predictable selectivity was 19 according to formula 5.2. 
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Figure 36: Separation of DNA and GFP. Buffer was 20 mM Tris at pH 8 [119]. Equilibration was done with 
2.0 ml buffer per well. 3 parallel samples were analysed for each tested condition. 1 ml of a mixture of GFP and 
DNA was added at each condition. Gradations of the color scheme are 10 % for GFP, 5 % for DNA and 2 for the 
dimensionless selectivity (see formula 5.2). After the determination of the DNA and GFP in the flow-through 
fraction the selectivity was calculated. 
The results confirmed the previous results with single components. The presence of 
multivalent salt for IEX1 had no effect; in contrast the binding of GFP to the adsorber was 
reduced on IEX2. Moreover, the binding of DNA was less affected by each salt composition 
Investigation of contaminant removal using anion exchanger membranes 
63 
for IEX2; it decreased for IEX1 at higher conductivities. The interaction of DNA with IEX1 
was abolished with concentrations of sodium chloride > 100 mM. The addition of phosphate 
up to 30 mM showed no significant effect, similar the increase of pH. Using IEX2 the 
breakthrough of DNA increased slightly with the addition of phosphate. The complementary 
results at several pH values showed similar trends to those seen for BSA (Figure 33 + 34). 
The range of conditions for higher protein binding increased with the pH on IEX1. At pH 6 
the affinity of GFP to IEX2 seemed to be higher in the presence of phosphate as well as 
chloride. Subsequently the data have been used to evaluate the selectivity. The visualization 
indicates the favored separation for IEX1 using 250 to 300 mM sodium chloride or lower in 
the combination with phosphate. The use of only phosphate up to 30 mM did not lead to a 
sufficient separation. Further, already 20 mM phosphate was able to separate GFP and DNA 
on IEX2. Complementary values for further pH values were summarized in the  
Appendix (8.3.2). 
In Figure 35 the sweet spot, with requirements of 90 % GFP recovery and 90 % DNA 
removal is visualized.  
 
Figure 37: Sweet spot analysis separation DNA and GFP. Evaluation of the data from Figure 34. The brighter 
area highlighting buffer conditions where a sufficient separation is possible. 
The high affinity of DNA to anion exchangers at the investigated conditions favors a 
purification step in flow-through mode. For both types of IEX appropriate conditions were 
found. A separation for IEX2 was possible with a slight increase of multivalent ions. Thus, it 
was not necessary to strongly raise the conductivity.  
The results of the study using single model molecules showed less influence of the salt on 
binding of proteins and phages. Therefore, the following investigations focused on the 
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purification performance of membrane to separate these molecules. Model solutions 
containing protein and phages were evaluated at different buffer conditions. The separation of 
GFP and phages was chosen to investigate the binding behaviour at low concentration of a 
contaminant and target molecule. In contrast to the binding capacity for BSA, the load used 
here was much smaller than capacity of the adsorber.  
 
 
Figure 38: Separation of phages and GFP. Buffer was 20 mM Tris at pH 8. Equilibration was done with 
2.0 ml buffer per well. 3 parallel samples were pooled and analysed for each tested condition. 1 ml mixed 
solution was added at each condition. Gradations of the color scheme are 10 % for GFP and 0.5 logs for phages. 
Based on the results for IEX1 it was expected that no condition in the observed operational 
window would be useful to separate phages and GFP. But quite favorable process conditions 
could be found; wherein at least 95 % of GFP was found in the flow-through and > 99 % of 
phages were bound to the membrane. In contrast to the purification of GFP in flow-through 
mode, those conditions are also suitable in bind and elute mode. If GFP represents a typical 
HCP it passes through the membrane adsorber while the phages were bound to it.  
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DNA, GFP and phages was evaluated as suitable model components to evaluate anion 
exchangers in flow-through mode for contaminant removal. The detection methods for the 
biomolecules were independent of the components of this model solution. Phages, GFP and 
DNA as model components represent molecules of real process media regarding size and 
binding properties. 
 
5.4 Comparison of the separation of molecules to larger device 
With the use of the screening device process conditions have been identified which enable the 
separation of contaminants and target molecules. In Chapter 2.4.2 the scalability for IEX1 and 
IEX2 regarding the influence of pH to bind bacteriophage ΦX174 has been shown. Further 
data on the influence of sodium chloride using a larger device also confirm the possibility of 
scale up (see Appendix 8.3). In this part now the scalability of the separation of DNA and 
phages using multivalent salt was investigated.  
A screening was performed using the 96-well membrane holder to evaluate the separation of a 
phage solution spiked with Salmon sperm DNA. The DNA concentration was 200 ng/ml. 
 
Figure 39: Separation of DNA and phages using phosphate. After equilibration with 2.0 ml 20 mM Tris 
buffer at a pH of 7.4, 1 ml of phage solutions was added to each well. Each buffer condition was testes 6 times. 
The initial infectivity titer was 1.5x10
7
 PFU/ml. 
30 mM sodium phosphate abolishes the binding of phage to IEX2 almost completely. The 
DNA content of each fraction was below the detection limit of 10 ng/ml.  
0.0
0.5
1.0
1.5
2.0
2.5
3.0
0 20 40 60 80 100
Sodium phosphate [mM/l] 
 L
R
V
Investigation of contaminant removal using anion exchanger membranes 
66 
The same device containing of 15 cm² membrane area was used according to the scale-up 
trials of Chapter 4.2.4. After equilibration using 50 ml, 150 ml of DNA-spiked phage solution 
was filtered at 10 ml/min. The buffer condition was similar to the screening: 20 mM Tris at 
pH 8. 30 mM sodium phosphate was added to separate DNA and phages. Three flow-through 
fractions of 50 ml were collected. For each fraction the DNA found to be below the detection 
limit of the test. The recovery of phages was 79 % analysed with the phage assay. The results 
confirmed the scalability of optimized buffer conditions for the separation of DNA and 
phages. 
 
5.5 Conclusion 
After implementation and testing the developed screening approach, the investigations in the 
second part of this thesis the platform was used for the characterization of contaminant 
binding using membrane adsorbers. Beside classical single molecule models like BSA or 
DNA, multi molecule model solutions were used to observe the contaminant binding 
properties of ion exchange membrane adsorbers regarding the effect of salts and pH on the 
performance. Furthermore, the binding of endotoxin and phages as trace impurities were 
investigated in a broad operational window.  
Anion exchanger having quaternary ammonium IEX1 or polyallylamine IEX2 as ligand were 
compared. Depending on the analysed molecule, effects in the slightly basic and acidic pH 
range and up to 150 mM multivalent salts and 1000 mM monovalent salt were shown. 
Optimized buffer conditions for binding different molecules could be determined. Similar to 
published data, it was found that DNA and endotoxins have a high affinity to the anion 
exchanger media in a broad operational window for both membranes. The binding of phages, 
GFP and BSA was less affected at higher concentrations of monovalent salt using the salt-
tolerant IEX2. The binding on IEX1 was strongly influenced by increased salt concentration 
even at a conductivity of 5 mS/cm. Multivalent salts have a greater effect on the binding 
performance for both membranes, but significantly stronger on IEX2. A lowering of protein 
and phage binding by the addition of multivalent salts compared to the addition of 
monovalent sodium chloride has been observed The effect of citrate was even greater 
compared to phosphate. 
As expected, with IEX1 a higher pH, farer away from the isoelectric point, reduced the effect 
of salt. In contrast, this was not valid for the binding using the polyallylamine ligand of the 
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weak anion exchanger IEX2. It was found that the binding in the presence of salt at slightly 
acidic conditions was improved. It was also possible to bind molecules even at or below the pI 
of the molecules using IEX2 as shown for phages and GFP. 
Green fluorescent protein and phage Phi X 174 turned out to be a practical model system for 
investigation contaminant removal with low-concentrated target molecules. Well suited buffer 
conditions for the separation of DNA and GFP were successfully determined. The model 
system identified different approaches for contaminant removal using both anion exchanger 
membrane adsorbers. The separation using IEX1 was in general ruled by the conductivity. 
Using IEX2 the type of salt was crucial for the separation of contaminant and target 
molecules. The use of multivalent ions, opened approaches for the use of anion exchangers in 
flow-through as well as in capturing mode, although contaminants may have the same charge 
like the membrane surface. 
Finally, it was possible to scale up and confirm the binding properties with larger devices. As 
well as for phage removal in Chapter 4, binding properties were successfully transferred using 
buffers which containing multivalent salts. 
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6 Summary and outlook 
In the course of the work presented here a new screening platform has been developed to 
characterize the contaminant removal in downstream processing using membrane adsorbers. 
Thus, the investigation of the influence of up to 32 buffer conditions on chromatographic 
performance of membrane adsorbers was performed in 3 hours, including buffer preparation 
and analysis. The developed 96-well membrane holder for screening applications showed 
sufficient reproducibility and enables the simultaneous investigation of membranes at 
different buffer conditions without the need for additional sealing like O-rings or preparation 
of discrete membrane pieces [132]. Furthermore, the results and knowledge gained here have 
been used for the development and commercialization of a disposable three-layer 96-well 
screening device for screening approaches [151]. 
Investigations on the performance and the scalability showed that the results can be 
transferred to a larger scale. Figure 40 represents the favored route for generating robust, 
scalable and economic membrane chromatography purification steps. 
 
Figure 40: Route of process development using membrane adsorbers. Chromatography high-throughput 
downstream process development HTPD together with design of experiments will be used as a tool to determine 
the design and control space of purification steps. 
The results of this thesis highlighted the need for screening tools for technology advancement 
in the field of membrane chromatography. It enables a large amount of process data to be 
generated and analyzed. This technique is of course not limited to ion exchanger membranes. 
For example, an obvious step is the investigation of hydrophobic membrane adsorbers for 
aggregate removal [13, 44, 115, 152, 153]. In respect to mixed-mode adsorbents with 
simultaneous different interaction modes of the ligand, it is of upmost importance to 
understand binding mechanisms behind. The increase in knowledge in membrane 
chromatography purification steps is probably the most important advancement. 
Chromatography is a major purification step in the production of biopharmaceuticals, 
therefore this screening approach can support the “Quality by Design” agenda of 
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pharmaceutical regulatory authorities [138, 143, 144], wherein an aim is to facilitation of 
release and change criteria of process parameters. Together with new concepts of parallelized 
detection methods, like size determination of biomolecules [154], this further accelerates the 
accumulation of process knowledge. Further, screening results can be used for modeling 
chromatography steps and predicting purification performance. An improvement, due to 
availability of large data sets, is the possibility to use data-driven models. This kind of “Black 
Box” modeling [155] enables the prediction, even when physical and chemical relationships 
are rather obscure unknown, which is true for complex process media at different buffer 
conditions in chromatography steps. 
This thesis reveals appropriate purification strategies in downstream processing. The present 
results showed an application which enables the concentration and purification of 
biomolecules. The removal of DNA fragments or host cell proteins in the purification of 
viruses or virus-like particles is of certain concern in purification [25]. An obvious application 
is the removal using anion exchangers at higher salt concentrations to remove DNA in flow-
through mode. The use of multivalent salt in combination with polyallylamine based 
membrane adsorber has further the advantage of the possible purification in flow-through 
mode at low conductivity. Further studies could evaluate the concentration and purification of 
viruses or virus-like particles using anion exchanger. Due to the effect of small amounts of 
multivalent salts, it is expected that viral target molecules will bind while HCP passes through 
the membrane. The increase of the concentration of multivalent ions could then be used to 
elute the virus particles. In the same step, other contaminants with a high affinity to the 
ligand, like DNA or endotoxins, remain on the adsorbent. A patent application was applied to 
purify viruses with quaternary ammonium IEX1 and polyallylamine based IEX2 membrane 
adsorbers using the effect of multivalent ions [156]. Next to dead-end filtration, membrane 
adsorbers in tangential filtration mode are also described for the use in purification of 
biomolecules from particle containing media [85]. It could be evaluated to transfer the 
knowledge of buffer effects based on screening results also to this application.  
Another interesting approach is the use of the salt-tolerant IEX2 to combine protein 
purification and desalting in a single step. Results in the thesis showed a binding of protein 
and phage molecules to the adsorber even at high monovalent salt concentrations. Prompting 
that multivalent ions can be used for elution using low-concentrated buffers the total salt 
concentration will be reduced. This might reduce further necessary steps in downstream 
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purification. It combines a contaminant removal with a desalting step using an anion 
exchanger in bind and elute mode. 
In the field of the development of newly modified membrane adsorbers the screening 
approach enables the implementation of methods for the rapid and parallel characterization of 
purification performances at several buffer conditions. The use of multi-molecule model 
solutions can be used to investigate parameters like the type of ligand, ligand density or pore 
size of the membranes. Thus, the development should not only be focused on binding capacity 
and the tolerances to buffer additives, but also on the effects on the selectivity. 
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8 Appendix 
8.1 Materials 
8.1.1 Chemicals and biomolecules 
The following chemicals and biomolecules were used for buffer preparation, screening studies 
and detection assays.  
Table 6: Chemicals. 
Product Manufacturer 
CHES  Sigma Corporation, St. Louis, USA 
Tris Roth, Karlsruhe, Germany 
BIS-Tris Roth, Karlsruhe, Germany 
Acetic acid Roth, Karlsruhe, Germany 
Citric acid Merck, Darmstadt, Germany 
Sodium acetate Roth, Karlsruhe, Germany 
Disodium phosphate Merck, Darmstadt, Germany 
Monosodium phosphate Merck, Darmstadt, Germany 
Sodium chloride Roth, Karlsruhe, Germany 
Hydrogen chloride Roth, Karlsruhe, Germany 
Sodium hydroxide Fluka Chemie AG 
Decon 90 Decon Laboratories Limited, United Kingdom 
Ascorbic acid Roth, Karlsruhe, Germany 
Acid sulphur Roth, Karlsruhe, Germany 
Ammonium molybdate Roth, Karlsruhe, Germany 
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Product Supplier 
Beta-Glucan-Blocker Kit Lonza, Basel, Switzerland 
Endotoxin, E. coli O55:B5 Lonza, Basel, Switzerland 
Nutrient Broth BD, Franklin Lakes, USA 
Nutrient Broth Agar BD, Franklin Lakes, USA 
Acetone Roth, Karlsruhe, Germany 
Ethanol, 96 % VWR International GmbH 
BCA-Assay Kit A&B Pierce, Rockford, USA 
PicoGreen® Invitrogen AG, Carlsbad, USA 
Endochrome-K Charles River 
Trypticase Soy Agar BD, Franklin Lakes, USA 
Trypticase Soy Broth BD, Franklin Lakes, USA 
 
A 1 % solution of the detergent Decon 90 was used for cleaning the pipetting tips of the 
robotic platform prior to each pipetting step using different buffers or during sampling.  
Table 7: Biomolecules. 
Substance Supplier 
BSA Kraeber, Ellerbek, Germany 
Salmon sperm DNA Biomol GmbH, Hamburg, Germany 
Calf thymus DNA Sigma, Deisenhofen, Germany 
Endotoxin Lonza Group Ltd, Basel, Switzerland 
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The GFP was produced by the cultivation of Pichia pastoris and Bacteriophage ΦX174 by the 
cultivation of E.coli. The purified Bacteriophage ΦX174 and cell-free GFP containing 
solutions were kindly donated by the R&D department at Sartorius-Stedim Biotech GmbH. 
For more details of the cultivation and components of the culture media see Appendix 8.1.5 
and 8.1.6. 
 
8.1.2 Buffers and buffer preparation 
Stock solutions were used for the preparation of the chromatographic media. Each stock 
solution was filtered through 0.2 µm. The pH was adjusted at room temperature. Table 8 
contains the buffers used.  
Table 8: Basic buffers. The conductivities were determined for a buffer concentration of 20 mM. 
pH range Buffer Conductivity 
4.0 – 5.5 Acetate 0.4 – 0.9 mS/cm 
6.0 – 7.0 BIS-Tris 0.5 – 1.6 mS/cm 
7.5 – 9.0 Tris 0.5 – 1.8 mS/cm 
9.5 – 10.0 CHES 0.4 – 1.4 mS/cm 
 
Two steps were necessary for the automatic preparation of buffers using the robotic platform. 
The calibration of the buffer system was done first. Acid was titrated with base depending on 
the buffer system. The amount of base and acid necessary to adjust a specific pH of a buffer 
was determined. 16 solutions were prepared, each with a different proportion of acid or base. 
The target molarity of each buffer was 20 mM. Three different types of buffer were prepared:  
- Acetate: the acid was titrated against the corresponding base 
- Tris, BIS-Tris: the base was kept constant and the amount of acid was varied 
- CHES: the acid was kept constant and the amount of base was varied 
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The determined functions correspond to the Henderson-Hasselbalch equation [157]. The 
buffers were only used in the pH range described in Table 8. 
 
Figure 41: Adjustment of pH for the different buffers. The pH was adjusted by the addition of base or acid. 
The percentage of acid or base refers to the concentration of CHES, Tris and BIS-Tris. In the case of acetate the 
percentage of acid refers to the total amount of the buffer. The calibrations were done at five different sodium 
chloride concentrations (0, 30, 50, 100 and 150 mM/l). The average pH values are shown. The deviation of the 
pH was ≤ 0.16. 
The performance using ion exchange chromatography in the downstream purification process 
depends inter alia on the conductivity of the feed solution. Sodium chloride was added in for 
adjustment of different conductivities. Figure 42 shows the conductivity with increasing 
concentration of sodium chloride. 
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Figure 42: Conductivity depending on sodium chloride concentration. The dependence of conductivity from 
the sodium chloride concentrations assumed to be linear. The conductivities were determined of 12 buffer 
preparations. 
The calibration data were stored in an Excel spreadsheet. The amount of acid or base needed 
to adjust the required pH was calculated by linear regression in order. The percentages of 
further components like protein, salt and water were determined next. Furthermore, the total 
volume of each buffer and the allocation of stock reservoirs were saved in the file. Reading 
the receipt from the Excel file, the robotic software calculates the piston stroke for transport 
and mixing the corresponding volumes. Based on the concentrations of the stock solutions 
and the percentage of the buffer any buffer composition could be mixed.  
According to Debye-Hueckel the salt concentration have influences on the activity of protons 
as affected by the addition of chloride ions [158]. An increasing sodium chloride 
concentration could cause a change to the pH during buffer preparation. The effect has not 
been considered in this thesis. The deviation of the pH value was < 0.2 during the 
experiments. An extended calibration protocol could also address this effect. 
Phosphate and citrate stock solutions for examining the influence of multivalent salt ions were 
prepared. The pH of the stock solution corresponds to the pH of the final buffer for the 
experiment. The multivalent salt was considered as a buffer component. 
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8.1.3 Equipment 
The following equipment was used for experimental setup 
Table 9: Equipment. 
Equipment Supplier 
Sartobind STIC® Membrane (IEX2) Sartorius Stedim Biotech GmbH, Goettingen, 
Germany 
Sartobind Q Membrane (IEX1) Sartorius Stedim Biotech GmbH, Goettingen, 
Germany 
Lissy 2002, modular automated liquid handling system, 
software Runner Version 7.1.7 
Zinsser Analytic GmbH, Frankfurt, Germany 
Tecan XSafire plate reader Tecan Group AG, Maennedorf, Switzerland 
Valves  Festo, Esslingen, Germany 
Pressure sensor VAM-40-V1/0-R1/8-EN Festo, Esslingen, Germany 
FLx800 Fluorescence Microplate Reader BioTek Instruments INC, Winooski, USA 
HPLC Dionex, pump system P580, sampler ASI-100, 
detector 170S/340S, Thermostat STH 585, Software 
Chromeleon v 6.8 
Dionex Corporation, Sunnywale, USA 
TSK 3000SWxl Tosoh Bioscienc, Stuttgart, Germany 
Sartobind Q MA75 Sartorius Stedim Biotech GmbH, Goettingen, 
Germany 
Vacuum filtration unit Sartorius Stedim Biotech GmbH, Goettingen, 
Germany 
96-well micro titer plate UV-Star flat Greiner, Kremsmuenster, Austria 
Petri dishes, 90mm Greiner, Kremsmuenster, Austria 
Masterblock 96-well 2 ml  Greiner, Kremsmuenster, Austria 
Vacuum pump 16612 Sartorius Stedim Biotech GmbH, Goettingen, 
Germany 
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Equipment Supplier 
Arium G11 VF  Sartorius Stedim Biotech GmbH, Goettingen, 
Germany 
Multipipette plus  Eppendorf AG, Hamburg, Germany 
ÄKTA prime Amersham Biosciences, Uppsala, Sweden 
Autoclave, Varioklave HP, Oberschleissheim, Germany 
Heating block, Thermomixer Eppendorf AG, Hamburg, Germany 
Falcon tubes Greiner, Kremsmuenster, Austria 
Polystyrene tubes Roth, Karlsruhe, Germany 
Analytic balance Genius Sartorius Stedim Biotech GmbH, Goettingen, 
Germany 
Photometer Genesys 10UV Thermo Fischer Scientific, Waltham, USA 
Shaker Vortex Gemmy industrial, MinChuan, Taiwan 
Pipette tip Sarstedt AG & Co, Nuernberg, Germany 
Sterile filter Minisart 0.2µm Sartorius Stedim Biotech GmbH, Goettingen, 
Germany 
96-well half area plates Greiner, Kremsmuenster, Austria 
 Water quench 3042 Koettermann, Uetze, Germany 
 
For further equipment for the cultivation to prepare GFP and Bacteriophage ΦX174 is 
described in Appendix 8.1.5 and 8.1.6. 
 
8.1.4 Software 
To program the working sequences on the robot and to control individual peripherals the 
software ZA runner from Zinsser Analytic (Frankfurt, Germany) was used. The assignment of 
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each pipetting step and buffer preparation was imported from Excel. For the calculation of 
buffers Microsoft Office Excel Solver tool was used. The reader server RdrOle4 controlled 
the Tecan plate reader and the measurement procedures. The evaluation of chromatograms 
was performed using the software Chromeleon 6.8 for the size exclusion chromatography and 
Unicorn for the FPLC.  
The data analysis and visualization was carried out using the program MATLAB® (The 
MathWorks, Inc, Natick, United States of America). The generation of contour plots was 
performed with the experimental data. Three basic commands have been used. 
- ‘Meshgrid’: In the experimental space, described by the influencing factors (for 
example, salt concentration and pH), a uniform matrix was created. The matrix was 
limited to the minimum and maximum value of each influencing parameter. The final 
resolution of the regression of influencing factors was set for 10 sections. 
- ‘Griddata’: This command was used to linearly interpolate the intermediate values 
specified by the uniform matrix to the experimental data. This method is based on a 
Delaunay triangulation of the data [159]. 
- ‘Contour’: This was the actual visualization. A contour plot of the dependent variable 
(for example, binding or LRV) was generated, where the dependent variable displayed 
as color with respect to the influencing factors. 
 
8.1.5 Preparation of Green Fluorescent Protein 
The fermentation of Pichia pastoris X-33 eGFP was performed using a BIOSTAT® Cplus 
bioreactor (Sartorius Stedim Biotech GmbH, Goettingen, Germany). Enhanced GFP (eGFP) 
shows a higher luminosity and allows the use of mammalian cells [160]. The used 
composition of the nutrient solution was given by the thesis of Boettner [161] (conductivity 
6 mS/cm, pH 7). The carbon source was 20 g/l glucose. After 40 h of cultivation 2.8 ml/(h*l) 
methanol was added for 24 h to initiate the production of GFP. The total fluid volume of the 
cultivation was 7.5 l. The fermentation was terminated after another 24 h. The fermentation 
broth was sedimented for 72 h at 4 °C. Two liter of supernatant were purified using a cross-
flow system (Vivaflow 200 0.2 µm PES and Vivaflow 50 100K RC, Sartorius Stedim Biotech 
GmbH, Goettingen, Germany). The volume of the concentrated solution was 190 ml. 
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Furthermore, a chromatographic step was used to separate further components. The solution 
was loaded to an anion exchanger membrane adsorber (Sartobind Q MA75, Sartorius Stedim 
Biotech GmbH, Goettingen, Germany). After washing with 40 ml buffer (20 mM Tris pH 8), 
a linear gradient elution (40 ml, 0 to 1 M sodium chloride in 20 mM Tris buffer pH 8) was 
used to collect several fractions of 5 ml. Each fraction was analyzed by size exclusion 
chromatography and fluorescence was measured. The buffers for size exclusion 
chromatography were used according to the recommended instructions of the manufacturer of 
the column. The fraction which showed the largest fluorescence as well as the expected GFP-
specific peak was portioned frozen at -40 C°. 
The protein concentration of the fraction of the highest fluorescence was determined by the 
bicinchoninic (BCA) assay. A reagent kit (PIERCE, Rockford, IL, USA) was used according 
to the instructions. The BSA equivalent concentration of the GFP stock solution was 
1.6 mg/ml.  
 
Figure 43: Determination of protein concentration using BCA. A dilution series of BSA was used to create a 
calibration. The linear calibration function was used to calculate the BSA equivalent protein concentration of the 
GFP. Before measurement the GFP stock solution was 30-fold diluted (extinction 0.68). 
 
8.1.6 Preparation of Bacteriophage ΦX174  
For the spiking studies a concentrated phage stock solution was prepared. The Bacteriophage 
 X174 (ATCC 13706-B1) was produced by a fermentation of Escherichia coli C (ATCC 
13706). In a disposable bioreactor (Biostat® 50L CultiBag RM, Sartorius Stedim Biotech 
GmbH, Goettingen, Germany) E.coli was grown. The fermentation volume was 20 l; the 
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media was 30 g/l Trypticase Soy broth (Sigma, Deisenhofen, Germany). After a certain cell 
density was achieved, the bacterial culture was inoculated with phages. The phage production 
continued for 4 h. Subsequently, the reaction was stopped by filtration. Cell harvest and sterile 
filtration were done using a depth filter cascade (Sartopure PP2 MidiCap 8 – 5 μm and 
Sartopore 2XLG 0.8 – 0.2 µm, Sartorius Stedim Biotech, Goettingen, Germany). By cross-
flow filtration (30 kDa Sartocon Slice Cassette, Sartorius Stedim Biotech, Goettingen, 
Germany) the permeate was reduced to a final volume of 600 ml. The next step was a 
precipitation. The solution was mixed with a polyethylene glycol solution of 30 %. For the 
separation the mixture was centrifuged at 8430 rpm for 90 min (Sorvall RC-6 centrifuge, 
Thermo Fisher Scientific, Bonn, Germany). The pellets were resuspended with 25 ml of the 
storage buffer and stored at -70 °C. The phage concentration of the stock solution was 
approximately 1x10
10
 PFU/ml. Furthermore, the stock solution was analyzed using the 
PicoGreen assay. A concentration of 1.1 µg/ml equivalent to salmon sperm DNA was 
determined. Because of the high dilution for phage spiking studies, no interferences were 
expected from the DNA. Thus, during the experiments using a phage spike, the DNA 
concentration was below the detection limit of the phage stock solution. 
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8.2 Methods 
The methods used are described in the following. As mentioned, detection assays are often 
influenced by the buffer conditions. Unless otherwise stated, during this thesis it was assumed 
that the effect of specific buffer conditions is equal for the initial feed solution and flow 
through or elution sample. During the screening, the initial solutions containing the target 
molecules were prepared from the same stock solution. During the experiments the detection 
method was performed at standard buffer conditions to determine the initial concentration. 
Published data and the measurements of initial solutions indicated the buffer conditions where 
the detection was still possible. This considerably reduced the required efforts during the 
analysis. Thus, the breakthrough or LRV could be determined. 
 
8.2.1 Photometric determination of protein and DNA 
The detection of BSA and DNA concentrations was performed by a photometric 
determination based on the Lambert-Beer law. The extinctions were measured at 280 nm for 
protein and 260 nm for DNA.  
 
Figure 44: Calibration of BSA using the Tecan plate reader at 280 nm. 24 different concentrations were 
prepared using the automated liquid handling system. Then two samples of each falcon tube were transferred 
into the 96-well plate. The buffer was 20 mM Tris at pH 7.4. The calibration was repeated three times. A 
standard procedure was implemented using the Zinsser control software to repeat the calibration several times. 
The limit of quantification was set at 0.1 mg/ml. 
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Figure 45: Calibration of DNA using the Tecan plate reader at 260 nm. 8 different concentrations were 
prepared using the automated liquid handling system. Then two samples of each falcon tube were transferred 
into the 96-well plate. The buffer was 20 mM Tris at pH 7.4. The limit of quantification was set at 1 µg/ml. 
 
8.2.2 Phosphate detection 
To exclude a cross-contamination of buffer components in adjacent wells of the 96-well 
holder the detection method of orthophosphate based on the formation of phosphomolybdate 
blue was used. All used equipment was cleaned using distilled water. Ammonium molybdate, 
sulphuric acid and ascorbic acid were mixed in an aqueous solution. Phosphomolybdatic acid 
is formed in an acidic environment with the presence of phosphate. Ascorbic acid reduces 
molybdate to phosphomolybdate blue. The detection reagent consists of 50 ml 100 g/l 
ascorbic acid, 50 ml 6 M sulphuric acid, 50 ml 25 g/l ammonium molybdate and 100 ml of 
distilled water. 500 µl of the reagent was mixed with 500 µl of sample solution in a 96-well 
collection plate. The mixture was shaken and heated for 10 min at 70 °C. 300 µm of each 
solution was transferred to a 96-well microtiter plate and measured at 820 nm using the Tecan 
plate reader. The quantification limit was defined as three times the blank value. 
 
8.2.3 GFP assay 
GFP was detected by the measurement of fluorescence using the Tecan plate reader. The 
excitation wavelength was 475 nm and the emission wavelength 509 nm. The bandwidth of 
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excitation and emission was 12 nm. Because lowest possible GFP concentrations were 
intended be used, the detection limit of GFP was evaluated. 
 
Figure 46: Fluorescence of GFP depending on the concentration. The GFP stock solution was diluted. The 
lowest concentration was 0.05 µg/ml. Buffer was 20 mM Tris at pH 8. Four samples were measured for each 
concentration. The gain was automatically determined by the plate reader. The maximum coefficient of variation 
was 10 % at a concentration of 0.05 µg/ml. 
The quantification limit was set at 0.15 µg/ml. During the screening experiments, the 
maximum GFP concentration was 1.6 µg/ml. In this concentration range the gain was fixed at 
150 for all measurements to ensure that the measurement scale was not exceeded. 
The fluorescence of GFP is influenced by the pH. The quantification of the fluorescence was 
performed using the fluorescent area.  
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Figure 47: Florescence of GFP depending on pH and sodium chloride. The concentration of GFP was 
0.8 µg/ml; this corresponded to 0.05 % of the GFP stock solution. Buffers were 20 mM sodium acetate at pH 4, 
20 mM BIS-Tris at pH 6, 20 mM Tris at pH 8 and 20 mM CHES at pH 10. For each buffer condition two 
samples were measured. 
Sufficient fluorescence for quantification was detected in the pH range from 6 to pH 10. The 
concentration of sodium chloride showed only little influence. 
 
8.2.4 Phage assay 
An infectivity assay was used to determine the concentration of Bacteriophage ΦX174. The 
method based on the same host cell organism (E. coli) as for the preparation of phages. Agar 
plates with nutrient medium were prepared. The bacteria are plated out; during the incubation 
E. coli cells will grow rapidly and form dense opaque bacterial lawns on the surface of the 
plate. The presence of infectious phage ΦX174 causes lysis of host cells. Thereby, clear areas, 
called plaques, were formed in the bacterial lawn due to bacterial lysis. A single plaque was 
defined as a plaque-forming unit (PFU). If necessary, samples were diluted several times in 
steps of 1:10 until it was possible to determine the numbers of plaques clearly separate from 
each other. 
To calculate removal, the phage titer was determined for each initial solution and each sample 
at various step dilutions. 150 µl of the E.coli suspension and sample were mixed with top agar 
(1.3 % Trypticase Soy Agar BD 211043). Then the mixture was plated on agar (4 % 
Trypticase Soy Agar BD 211043 in). After incubation at 37 °C for 24 hours, plaque-forming 
units were counted. The titer was calculated by 
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SampleV
D
x
E
P
Titer           (8.1) 
Where P was the number of countable plaques, E the sum of weighting, D the lowest 
evaluated dilution and VSample the volume of the sample. Starting from the first countable 
dilution with E = 1, the weighting decreases by a factor of 10 for each further dilution. 
When no plaque was found after incubation, the detection limit of the phage assay was used. 
The probability of the detection of phages was assumed to be 95 %. According to the relevant 
guidelines the detection limit clim was calculated at approximately 20 PFU/ml. 
SampleV
c
)05.0ln(
lim           (8.2) 
For each sample a parallel determination of the phage titer was performed. To evaluate the 
deviation of the LRV the coefficient of variation of phage titer was determined. For three 
different phage concentrations the standard deviation was calculated. Assuming that the first 
concentration in Table 10 was the spiking solution, the deviation of LRV was calculated with 
respect to the lower phage levels in Table 10 using the quadratic error propagation. 
Table 10: Deviation of ΦX174 plaque assay. 
c [PFU/ml] Standard deviation 
[PFU/ml] 
Coefficient of variation 
[%] 
LRV 
1.50E+07 2.93E+06 19.5 - 
5.99E+03 1.90E+03 31.8 3.14 ±0.24 
5.86E+01 3.43E+01 58.5 5.27 ±0.47 
 
 
8.2.5 DNA assay 
The quantification of low-concentrated salmon sperm and calf thymus DNA was performed 
using the Quant-iT™ PicoGreen® assay according to the manufacturer’s instructions. For this 
a 10-fold TE stock buffer (100 mM Tris pH 7.5 and 10 mM EDTA) was prepared. The 
PicoGreen dsDNA reagent was diluted 1 to 200 by mixing 20 µl reagents with 3980 µl using 
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TE-buffer. During the calibration for each type of DNA a stock solution of 2 mg/ml was 
prepared in TE-buffer and diluted in three steps to 2 µg/ml. In further dilution steps, using 
TE-buffer, several concentrations with a total volume of 100 µl were prepared for the 
standard curve. Each DNA solution was mixed with 100 µl PicoGreen® reagent. The mixture 
was shaken for 3 min and measured using the Tecan plate reader (excitation wavelength 
480 nm, emission wavelength 520 nm, gain 100). 
Table 11: Protocol for preparing PicoGreen® standard curve. 
2µg/ml DNA [µl] TE-Puffer [µl] c DNA [ng/ml] 
0 100 0 
0.1 99.9 0.2 
1 99 2 
5 95 10 
10 90 20 
25 75 50 
50 50 100 
75 25 150 
90 10 180 
100 0 200 
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Figure 48: Standard curve of DNA using the PicoGreen® assay. The limit of quantification was set at 10 
ng/ml due to a deviation > 10 % of the calculated value to the nominal values by using a linear regression. The 
relationship between measurement signal and setpoint was no more linear. A change of the surface tension, for 
example, caused by DNA, can change the curvature of a liquid surface. This changing of the path length in the 
well of a microtiter plate influenced the measurement signal according to the Beer-Lambert law [162]. 
In order to confirm the functionality of the detection reaction, the signal of the initial 
concentrations was compared for each buffer condition. It was shown that the detection signal 
decreases for lower pH. Furthermore, the effect of salt was more crucial for the detection of 
calf thymus DNA. 
 
Figure 49: Influence of salt and pH on the PicoGreen® assay for calf thymus DNA. The buffers used are 
described in Chapter 8.1.2. The DNA concentration was 100 ng/ml. 
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Figure 50: Influence of salt and pH on the PicoGreen® assay for salmon sperm DNA. The buffers used 
corresponded to those specified in Chapter 8.1.2. The DNA concentration was 100 ng/ml. 
 
8.2.6 Endotoxin assay 
The LRV was determined using the kinetic chromogenic limulus amebocyte lysate test 
according to the manufacturer’s instructions. It is based on coloration caused by the contact of 
the sample containing endotoxin with a mixture of lysate and chromogenic substrate [163]. 
The rate of formation of the dye is proportional to the concentration of endotoxin. 
The equipment in contact with endotoxins was treated with 1 M sodium hydroxide for 30 min 
or heated at 200 °C for 4 hours. 50 µl of substrate was mixed with the sample in a 96-well 
half-area plate. Because glucan can interfere with the detection assay, a ß-glucan blocker was 
added. The kinetic reaction was measured continuously at 405 nm at a temperature of 37 °C 
using the Tecan plate reader. The required time (onset time) was determined to reach an 
absorption value of 0.8. By logarithmic calculus a linear relationship between time and 
endotoxin concentration was found. The log reduction value was calculated similar to the 
phage assay. The detection limit of the assay was set according to the lowest value of the 
standard curve. A threefold determination was performed for each sample.  
As for the other assays the effect of various buffer conditions was evaluated. In general, for 
each buffer condition a standard curve should be set up. Thus, during the screening the 
number of data points increased to very high scores. To circumvent this disadvantage standard 
curves at different conditions were show in a very similar slope of the linear functions. The 
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presence of salt or a change of the pH changes the rate of the reaction uniformly for different 
concentrations by only shifting the curves on the x-axis, but not changing the slope 
 
Figure 51: Influence of salt and pH on the endotoxin assay. For different conditions linear standard curves 
were determined and compared. The endotoxin concentration was between 0.2 and 100 EU/ml. The coefficient 
of variation of the slopes at different buffer conditions was 4.9 %.  
Therefore only a calibration curve at pH 7.5 was established. The samples and dilutions of the 
initial solutions were analyzed on the same microtiter plate. For the screening studies the 
initial solution of 500 EU/ml was diluted to 1 EU/ml (OnsetIs) using the same buffer. By the 
comparison of the onset time of the calibration curve at 1 EU/ml (OnsetSTD) to the diluted 
initial concentration the deviation caused by the specific buffer condition could be calculated. 
Due to the relative change of the reaction time, the measured values (OnsetSample) of the 
samples were corrected to the calibration curve (OnsetSampleSTD).  
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Thus, the concentrations in the flow-through fraction and the LRV were calculated using the 
calibration curve (20 mM Tris pH 7.5) of each run. The coefficient of variation for the 
calculated endotoxin concentration was approximately 12 %. 
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8.2.7 Measurements using a FPLC system or a peristaltic pump  
For scale-up studies the MA15 device containing of 15 cm² membrane area was used. Protein-
binding studies were performed using the Fast Protein Liquid Chromatography (FPLC) 
system ÄKTA prime. After flushing all tubings of the FPLC, the absorbance of the initial 
protein was determined by loading 20 ml of the protein solution to the system and through the 
flow through cell until a stable reading was reached. Then the tubing was flushed again with 
buffer to reach a 0-reading again. Subsequently, the vented device was connected and flushed 
with 30 ml buffer. The void volume of the chromatographic system including the membrane 
adsorber device was detected using 2 % acetone and determined to 2.17 ml ±0.23. The 
breakthrough curve was recorded at a flow rate of 15 ml/min. The acquired data was exported 
to an Excel file. The area below the breakthrough curve was integrated to the similar load as 
in the screening experiments. The binding capacity at a certain loading was calculated by 
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Where VLoad is the volume of a specific load, VV
 
the void volume, UVmax the detection signal 
of the initial concentration, ci the initial concentration and A the membrane area in the device. 
The calculation relies on the linearity of the UV signal in the concentration range used which 
is depicted in Figure 52.  
 
Figure 52: Evaluation of the linearity of the UV 280 nm signal by the ÄKTA prime. Concentrations up to 
3 mg/ml were used for the scale-up studies. The linearity was confirmed loading 20 ml of 10 different 
concentrations ranging from 0.1 to 3 mg/ml to the ÄKTA prime. 
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For phage studies at a larger scale a multi-channel peristaltic pump was used. The devices 
were vented according to the manufacturer’s recommendations and flushed using 15 ml buffer 
each. During flushing the flow rate was adjusted to 10 ml/min (corresponding to 24 MV/min). 
Two devices were filtrated simultaneous. After flushing, 250 ml of the phage solution was 
loaded to each device. Three fractions of 20 ml were collected after 30, 150 and 230 ml of 
flow-through. Each fraction was analyzed with the plaque assay. It was found that the 
determined LRV of all three fractions were within the range of variation for the assay. The 
constant LRV confirmed that the loaded amount of phages was lower than the expected 
binding capacity during all phage removal experiments in this thesis. Otherwise a decreasing 
LRV should have been observed. After each test the tubings of the peristaltic pump were 
sanitized using 60 ml 1 M/l sodium hydroxide and 200 ml distilled water. 
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8.3 Supplementary results 
8.3.1 Determination of volume correction factor and pipetting error 
Table 12: Volume correction factor and estimation of pipetting error. The calculation of the volume 
correction factor (Volcor) and pipetting variation was determined for n = 5 measurements for each tip. The 
coefficients of variation are given for the 8 pipetting tips. Furthermore  
Volume
1
 Characteristics Tip 1 Tip 2 Tip 3 Tip 4 Tip 5 Tip 6 Tip 7 Tip 8 Tip 1-8 
50 Volcor 1.47 2.09 2.22 1.52 1.86 1.81 1.58 1.74 1.79
3
 
 Variation
2
 5.29 3.46 3.06 5.29 3.46 2.00 4.16 3.06 5.12
4
 
100 Volcor 1.25 1.54 1.61 1.27 1.45 1.37 1.36 1.40 1.41
3
 
 Variation
2
 3.46 1.15 3.00 3.21 2.52 1.53 3.00 2.65 2.84
4
 
300 Volcor 1.10 1.19 1.23 1.11 1.16 1.16 1.13 1.17 1.16
3
 
 Variation
2
 1.07 0.67 0.69 0.51 0.58 0.51 0.58 0.33 0.97
4
 
500 Volcor 1.06 1.11 1.14 1.06 1.10 1.09 1.08 1.11 1.09
3
 
 Variation
2
 0.12 0.31 0.95 0.90 0.35 0.20 0.20 0.12 0.68
4
 
800 Volcor 1.04 1.07 1.08 1.04 1.07 1.06 1.06 1.06 1.06
3
 
 Variation
2
 0.38 0.51 0.19 0.19 0.07 0.38 0.14 0.19 0.45
4
 
200 Volcor 1.02 1.04 1.05 1.01 1.03 1.04 1.02 1.04 1.03
3
 
 Variation
2
 0.68 0.40 0.33 0.30 0.40 0.31 1.89 0.15 0.43
4
 
5000 Volcor 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.003 
 Variation
2
 0.09 0.08 0.16 0.06 0.32 0.09 0.05 0.06 0.52
4
 
1
 Pipetted volume [µl]
 
2
 Coefficient of variation [%] 
3
 Average of all tips [%] 
4
 Between all tips [%] 
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8.3.2 Separation of DNA and GFP 
The following results represent the separation of GFP and DNA at various pH values. The test 
procedure was explained in Chapter 5.3.2. 
 
 
 
Figure 53: Separation of DNA and GFP at pH 6. Buffer was 20 mM BIS-Tris. 
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Figure 54: Separation of DNA and GFP at pH 7. Buffer was 20 mM BIS-Tris. 
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Figure 55: Separation of DNA and GFP at pH 9. Buffer was 20 mM Tris. 
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